AptarGroup (ATR) 10-Q 30 Jul 21 2021 Q2 Quarterly report Financial data

COVER

COVER - shares	6 Months Ended
	Jun. 30, 2021	Jul. 23, 2021
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jun. 30, 2021
Entity File Number	1-11846
Entity Registrant Name	AptarGroup, Inc
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	36-3853103
Entity Address, Address Line One	265 EXCHANGE DRIVE
Entity Address, Address Line Two	SUITE 100
Entity Address, City or Town	CRYSTAL LAKE
Entity Address, State or Province	IL
Entity Address, Postal Zip Code	60014
City Area Code	815
Local Phone Number	477-0424
Title of 12(b) Security	Common Stock, $.01 par value
Trading Symbol	ATR
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		65,959,499
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q2
Entity Central Index Key	0000896622
Amendment Flag	false

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Income Statement [Abstract]
Net Sales	$ 811,032	$ 699,305	$ 1,587,786	$ 1,420,858
Operating Expenses:
Cost of sales (exclusive of depreciation and amortization shown below)	523,050	441,702	1,011,755	892,958
Selling, research & development and administrative	140,913	123,365	275,261	249,557
Depreciation and amortization	57,790	56,429	115,228	107,235
Restructuring initiatives	4,876	7,331	8,548	12,170
​Total Operating Expenses	726,629	628,827	1,410,792	1,261,920
Operating Income	84,403	70,478	176,994	158,938
Other Income (Expense):
Interest expense	(7,175)	(8,734)	(14,590)	(17,122)
Interest income	624	175	1,005	350
Net investment (loss) gain	(1,611)	0	15,198	0
Equity in results of affiliates	81	(328)	(434)	(1,127)
Miscellaneous, net	(2,028)	(923)	(2,991)	(2,335)
​Total Other Expense	(10,109)	(9,810)	(1,812)	(20,234)
Income before Income Taxes	74,294	60,668	175,182	138,704
Provision for Income Taxes	19,020	18,808	35,969	41,594
Net Income	55,274	41,860	139,213	97,110
Net Loss (Income) Attributable to Noncontrolling Interests	2	(21)	15	(18)
Net Income Attributable to AptarGroup, Inc.	$ 55,276	$ 41,839	$ 139,228	$ 97,092
Net Income Attributable to AptarGroup, Inc. per Common Share:
Basic (in dollars per share)	$ 0.84	$ 0.65	$ 2.12	$ 1.51
Diluted (in dollars per share)	$ 0.81	$ 0.63	$ 2.05	$ 1.47
Average Number of Shares Outstanding:
Basic (in shares)	65,818	64,262	65,525	64,135
Diluted (in shares)	68,086	66,384	67,869	66,246
Dividends per Common Share (in dollars per share)	$ 0.38	$ 0.36	$ 0.74	$ 0.72

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Statement of Comprehensive Income [Abstract]
Net Income	$ 55,274	$ 41,860	$ 139,213	$ 97,110
Other Comprehensive Income (Loss):
Foreign currency translation adjustments	21,109	19,096	(27,373)	(23,133)
Changes in derivative gains (losses), net of tax	289	(733)	809	750
Defined benefit pension plan, net of tax
Actuarial gain, net of tax	123	0	442	0
Amortization of prior service cost included in net income, net of tax	32	72	65	143
Amortization of net loss included in net income, net of tax	2,354	1,368	4,708	2,933
Total defined benefit pension plan, net of tax	2,509	1,440	5,215	3,076
Total other comprehensive income (loss)	23,907	19,803	(21,349)	(19,307)
Comprehensive Income	79,181	61,663	117,864	77,803
Comprehensive Loss (Income) Attributable to Noncontrolling Interests	2	(22)	15	(19)
Comprehensive Income Attributable to AptarGroup, Inc.	$ 79,183	$ 61,641	$ 117,879	$ 77,784

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Assets
Cash and equivalents	$ 291,495	$ 300,137
Short-term investments	0	243
Total Cash and equivalents and Short-term investments	291,495	300,380
Accounts and notes receivable, less current expected credit loss ("CECL") of $5,601 in 2021 and $5,918 in 2020	635,847	566,623
Inventories	429,440	379,379
Prepaid and other	135,672	122,613
Total Current Assets	1,492,454	1,368,995
Land	30,761	28,334
Buildings and improvements	605,506	579,616
Machinery and equipment	2,829,642	2,808,623
Property, Plant and Equipment, Gross	3,465,909	3,416,573
Less: Accumulated depreciation	(2,241,454)	(2,217,825)
​Property, Plant and Equipment, Net	1,224,455	1,198,748
Investments in equity securities	65,200	50,087
Goodwill	887,741	898,521
Intangible assets, net	322,015	344,309
Operating lease right-of-use assets	61,583	69,845
Miscellaneous	56,654	59,548
Total Other Assets	1,393,193	1,422,310
Total Assets	4,110,102	3,990,053
Current Liabilities:
Notes payable, revolving credit facility and overdrafts	2,965	52,200
Current maturities of long-term obligations, net of unamortized debt issuance costs	67,243	65,666
Accounts payable, accrued and other liabilities	712,358	662,463
Total Current Liabilities	782,566	780,329
Long-Term Obligations, net of unamortized debt issuance costs	1,048,928	1,054,998
Deferred income taxes	26,183	37,242
Retirement and deferred compensation plans	151,260	145,959
Operating lease liabilities	45,769	52,212
Deferred and other non-current liabilities	68,733	68,528
Commitments and contingencies	0	0
​Total Deferred Liabilities and Other	291,945	303,941
AptarGroup, Inc. stockholders’ equity
Common stock, $.01 par value, 199 million shares authorized, 70.2 and 69.5 million shares issued as of June 30, 2021 and December 31, 2020, respectively	702	695
Capital in excess of par value	898,382	849,161
Retained earnings	1,734,638	1,643,825
Accumulated other comprehensive loss	(303,058)	(281,709)
Less: Treasury stock at cost, 4.3 and 4.5 million shares as of June 30, 2021 and December 31, 2020, respectively	(344,382)	(361,583)
Total AptarGroup, Inc. Stockholders’ Equity	1,986,282	1,850,389
Noncontrolling interests in subsidiaries	381	396
Total Stockholders’ Equity	1,986,663	1,850,785
Total Liabilities and Stockholders’ Equity	$ 4,110,102	$ 3,990,053

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Accounts and notes receivable, allowance for credit loss (in dollars)	$ 5,601	$ 5,918
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	199,000,000	199,000,000
Common stock, shares issued (in shares)	70,200,000	69,500,000
Treasury stock (in shares)	4,300,000	4,500,000

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (Unaudited) - USD ($) $ in Thousands	Total	Cumulative Effect, Period of Adoption, Adjustment	Retained Earnings	Retained EarningsCumulative Effect, Period of Adoption, Adjustment	Accumulated Other Comprehensive (Loss) Income	Common Stock Par Value	Treasury Stock	Capital in Excess of Par Value	Non- Controlling Interest
Beginning balance at Dec. 31, 2019	$ 1,572,252	$ (1,377)	$ 1,523,820	$ (1,377)	$ (341,948)	$ 686	$ (381,238)	$ 770,596	$ 336
Increase (Decrease) in Stockholders' Equity
Net income (loss)	97,110		97,092						18
Foreign currency translation adjustments	(23,133)				(23,134)				1
Changes in unrecognized pension gains (losses) and related amortization, net of tax	3,076				3,076
Changes in derivative gains (losses), net of tax	750				750
Stock awards and option exercises	43,451					4	10,532	32,915
Cash dividends declared on common stock	(46,143)		(46,143)
Ending balance at Jun. 30, 2020	1,645,986		1,573,392		(361,256)	690	(370,706)	803,511	355
Beginning balance at Mar. 31, 2020	1,587,623		1,554,665		(381,058)	689	(372,573)	785,567	333
Increase (Decrease) in Stockholders' Equity
Net income (loss)	41,860		41,839						21
Foreign currency translation adjustments	19,096				19,095				1
Changes in unrecognized pension gains (losses) and related amortization, net of tax	1,440				1,440
Changes in derivative gains (losses), net of tax	(733)				(733)
Stock awards and option exercises	19,812					1	1,867	17,944
Cash dividends declared on common stock	(23,112)		(23,112)
Ending balance at Jun. 30, 2020	1,645,986		1,573,392		(361,256)	690	(370,706)	803,511	355
Beginning balance at Dec. 31, 2020	1,850,785		1,643,825		(281,709)	695	(361,583)	849,161	396
Increase (Decrease) in Stockholders' Equity
Net income (loss)	139,213		139,228						(15)
Foreign currency translation adjustments	(27,373)				(27,373)
Changes in unrecognized pension gains (losses) and related amortization, net of tax	5,215				5,215
Changes in derivative gains (losses), net of tax	809				809
Stock awards and option exercises	66,429					7	17,201	49,221
Cash dividends declared on common stock	(48,415)		(48,415)
Ending balance at Jun. 30, 2021	1,986,663		1,734,638		(303,058)	702	(344,382)	898,382	381
Beginning balance at Mar. 31, 2021	1,900,795		1,704,336		(326,965)	700	(352,282)	874,623	383
Increase (Decrease) in Stockholders' Equity
Net income (loss)	55,274		55,276						(2)
Foreign currency translation adjustments	21,109				21,109
Changes in unrecognized pension gains (losses) and related amortization, net of tax	2,509				2,509
Changes in derivative gains (losses), net of tax	289				289
Stock awards and option exercises	31,661					2	7,900	23,759
Cash dividends declared on common stock	(24,974)		(24,974)
Ending balance at Jun. 30, 2021	$ 1,986,663		$ 1,734,638		$ (303,058)	$ 702	$ (344,382)	$ 898,382	$ 381

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Cash Flows from Operating Activities:
Net Income	$ 139,213	$ 97,110
Adjustments to reconcile net income to net cash provided by operations:
Depreciation	95,606	86,901
Amortization	19,622	20,334
Stock-based compensation	21,805	17,603
Provision for CECL	(240)	1,089
Loss (gain) on disposition of fixed assets	5	(46)
Gain on remeasurement of equity securities	(15,198)	0
Deferred income taxes	(6,865)	9
Defined benefit plan expense	14,650	11,550
Equity in results of affiliates	434	1,127
Change in fair value of contingent consideration	1,950	0
Changes in balance sheet items, excluding effects from foreign currency adjustments:
Accounts and other receivables	(76,735)	(25,625)
Inventories	(55,873)	(13,241)
Prepaid and other current assets	(19,793)	(16,936)
Accounts payable, accrued and other liabilities	69,139	64,620
Income taxes payable	(5,261)	(8,446)
Retirement and deferred compensation plan liabilities	(9,657)	(5,916)
Other changes, net	2,779	(2,447)
Net Cash Provided by Operations	175,581	227,686
Cash Flows from Investing Activities:
Capital expenditures	(137,039)	(122,986)
Proceeds from sale of property, plant and equipment	4,571	4,130
Maturity of short-term investment	243	0
Acquisition of business, net of cash acquired and release of escrow	(4,834)	(159,570)
Acquisition of intangible assets, net	0	(3,612)
Investment in equity securities	0	(34,044)
Notes receivable, net	(29)	(1,045)
Net Cash Used by Investing Activities	(137,088)	(317,127)
Cash Flows from Financing Activities:
Proceeds from notes payable and overdrafts	7,410	14,464
Repayments of notes payable and overdrafts	(4,615)	(27,788)
Repayments and proceeds of short term revolving credit facility, net	(52,000)	125,000
Proceeds from long-term obligations	7,888	1,316
Repayments of long-term obligations	(7,001)	(4,067)
Credit facility costs	(1,718)	0
Payment of contingent consideration obligation	0	(1,500)
Dividends paid	(48,415)	(46,143)
Proceeds from stock option exercises	53,038	30,058
Net Cash (Used) Provided by Financing Activities	(45,413)	91,340
Effect of Exchange Rate Changes on Cash	(6,555)	8,522
Net (Decrease) Increase in Cash and Equivalents and Restricted Cash	(13,475)	10,421
Cash and Equivalents and Restricted Cash at Beginning of Period	304,970	246,973
Cash and Equivalents and Restricted Cash at End of Period	$ 291,495	$ 257,394

CONDENSED CONSOLIDATED STATEM_5

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020	Jun. 30, 2020	Dec. 31, 2019
Restricted cash included in the line item prepaid and other on the Condensed Consolidated Balance Sheets as shown below represents amounts held in escrow.
Cash and equivalents	$ 291,495	$ 300,137	$ 247,656
Restricted cash included in prepaid and other	0		9,738
Total Cash and Equivalents and Restricted Cash shown in the Statement of Cash Flows	$ 291,495	$ 304,970	$ 257,394	$ 246,973

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES BASIS OF PRESENTATION The accompanying unaudited Condensed Consolidated Financial Statements include the accounts of AptarGroup, Inc. and our subsidiaries. The terms “AptarGroup”, “Aptar”, “Company”, “we”, “us” or “our” as used herein refer to AptarGroup, Inc. and our subsidiaries. All significant intercompany accounts and transactions have been eliminated. Certain previously reported amounts have been reclassified to conform to the current period presentation. In the opinion of management, the unaudited Condensed Consolidated Financial Statements (the “Condensed Consolidated Financial Statements”) include all normal recurring adjustments necessary for a fair statement of consolidated financial position, results of operations, comprehensive income, changes in equity and cash flows for the interim periods presented. The accompanying Condensed Consolidated Financial Statements have been prepared by the Company, pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) have been condensed or omitted pursuant to such rules and regulations, although we believe that the disclosures made are adequate to make the information presented not misleading. Also, certain financial position data included herein was derived from the audited Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2020 but does not include all disclosures required by U.S. GAAP. Accordingly, these Condensed Consolidated Financial Statements and related notes should be read in conjunction with the audited Consolidated Financial Statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2020. The results of operations of any interim period are not necessarily indicative of the results that may be expected for the year. Beginning July 1, 2018, we have applied highly inflationary accounting for our Argentinian subsidiary pursuant to U.S. GAAP. We have changed the functional currency from the Argentinian peso to the U.S. dollar. We remeasure our peso denominated assets and liabilities using the official rate. In September 2019, the President of Argentina reinstituted exchange controls restricting foreign currency purchases in an attempt to stabilize Argentina’s financial markets. As a result of these currency controls, a legal mechanism known as the Blue Chip Swap emerged in Argentina for reporting entities to transfer U.S. dollars. The Blue Chip Swap rate has diverged significantly from Argentina’s “official rate” due to the economic environment. During the second quarter of 2020, we transferred U.S. dollars into Argentina through the Blue Chip Swap method and we recognized a gain of $1.0 million. This gain helped to offset foreign currency losses due to our Argentinian peso exposure and devaluation against the U.S. dollar. Our Argentinian operations contributed less than 2.0% of consolidated net assets and revenues as of and for the six months ended June 30, 2021. There continues to be many uncertainties regarding the current COVID-19 pandemic, including the availability and adoption of approved vaccines within certain areas of the world and the potential for additional governmental actions that may be taken and/or extended in response to any further resurgence of the virus. However, in contrast to the preceding year, we are currently seeing a limited impact on our business related directly to the COVID-19 pandemic as economic activity and customer and product mix are approaching pre-pandemic levels. No impairments were recorded as of June 30, 2021 related to the COVID-19 pandemic. Due to uncertainty surrounding the situation, future results could be negatively affected by the pandemic and therefore our results could be materially impacted. ADOPTION OF RECENT ACCOUNTING STANDARDS Changes to U.S. GAAP are established by the Financial Accounting Standards Board (“FASB”) in the form of Accounting Standards Updates (“ASUs”) to the FASB’s Accounting Standards Codification. Effective January 1, 2021, we adopted ASU 2020-10, Codification Improvements, which updates various codification topics by clarifying or improving disclosure requirements to align with the SEC's regulations, and no material impacts were noted. Effective January 1, 2020, we adopted ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, issued by the FASB in June 2016, as well as the clarifying amendments subsequently issued. We applied the guidance using a modified retrospective approach and accordingly recognized an amount of $1.4 million as the cumulative adjustment to opening retained earnings in the first quarter of 2020. This is based on management's best estimates of specific losses on individual exposures particularly on current trade receivables, as well as the time value of money and reasonable and supportable information that is available at the reporting date about past events, current conditions and forecasts of future economic conditions. On an ongoing basis, we will contemplate forward-looking economic conditions in recording lifetime expected credit losses for our financial assets measured at cost, such as our trade receivables and certain other assets. In January 2017, the FASB issued ASU 2017-04, which provides guidance to simplify how an entity is required to test goodwill for impairm ent by eliminating Step 2 from the goodwill impairment test. As a result, impairment charges are required for the amount by which a reporting unit’s carrying amount exceeds its fair value up to the amount of its allocated goodwill. We adopted the standard on January 1, 2020 and did not record any impairment charges. In August 2018, the FASB issued ASU 2018-13, which amends disclosure requirements for fair value measurements. The new standard modifies disclosure requirements including removing requirements to disclose the valuation process for Level 3 measurements and adding requirements to disclose the changes in unrealized gains and losses for the period included in other comprehensive income for recurring Level 3 fair value measurements and the range and weighted average of significant unobservable inputs used to develop Level 3 measurements. We adopted the standard on January 1, 2020 and no material impacts were noted. In August 2018, the FASB issued ASU 2018-14, which amends disclosure requirements for defined benefit pension and other postretirement plans. The amendments in this update remove disclosures that are no longer considered cost beneficial, clarify the specific requirements of disclosures, and add disclosure requirements identified as relevant. We adopted the standard during the fourth quarter of 2020 and appropriate disclosures are included in the notes to the financial statements to the extent applicable. The provisions of the new standard do not have any effect on our financial statements. In August 2018, the FASB issued ASU 2018-15 to help entities evaluate the accounting for fees paid by a customer in a cloud computing arrangement (hosting arrangement) by providing guidance for determining when the arrangement includes a software license. The amendments in this update align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). Accordingly, the amendments require an entity (customer) in a hosting arrangement that is a service contract to follow the guidance in Subtopic 350-40 to determine which implementation costs to capitalize as an asset related to the service contract and which costs to expense. The amendments also require the entity (customer) to expense the capitalized implementation costs of a hosting arrangement that is a service contract over the term of the hosting arrangement, which includes reasonably certain renewals. We adopted the standard on January 1, 2020 and no material impacts were noted. Other accounting standards that have been issued by the FASB or other standards-setting bodies did not have a material impact on our Condensed Consolidated Financial Statements. INCOME TAXES We compute taxes on income in accordance with the tax rules and regulations of the many taxing authorities where the income is earned. The income tax rates imposed by these taxing authorities may vary substantially. Taxable income may differ from pre-tax income for financial accounting purposes. To the extent that these differences create timing differences between the tax basis of an asset or liability and our reported amount in the financial statements, an appropriate provision for deferred income taxes is made. We maintain our assertion that the cash and distributable reserves at our non-U.S. affiliates are indefinitely reinvested. At June 30, 2021, under currently enacted laws, we do not have a balance of foreign earnings that will be subject to U.S. taxation. We will provide for the necessary withholding and local income taxes when management decides that an affiliate should make a distribution. These decisions are made taking into consideration the financial requirements of the non-U.S. affiliates and the global cash management goals of the Company. We provide a liability for the amount of unrecognized tax benefits from uncertain tax positions. This liability is provided whenever we determine that a tax benefit will not meet a more-likely-than-not threshold for recognition. We are subject to the examination of our returns and other tax matters by the U.S. Internal Revenue Service and other tax authorities and governmental bodies. We believe that an adequate provision for any adjustments that may result from tax examinations exists. However, the outcome of tax audits cannot be predicted with certainty. If any issues addressed in our tax audits are resolved in a manner inconsistent with our expectations, we could be required to adjust its provision for income taxes in the period such resolution occurs. The resolution of each of these audits is not expected to be material to our Condensed Consolidated Financial Statements.

REVENUE

REVENUE	6 Months Ended
	Jun. 30, 2021
Revenue from Contract with Customer [Abstract]
REVENUE	REVENUE Revenue by segment and geography for the three and six months ended June 30, 2021 and 2020 is as follows: For the Three Months Ended June 30, 2021 Segment Europe Domestic Latin Asia Total Pharma $ 212,220 $ 93,527 $ 5,294 $ 14,302 $ 325,343 Beauty + Home 192,371 103,679 38,882 25,314 360,246 Food + Beverage 32,402 71,974 11,885 9,182 125,443 Total $ 436,993 $ 269,180 $ 56,061 $ 48,798 $ 811,032 For the Three Months Ended June 30, 2020 Segment Europe Domestic Latin Asia Total Pharma $ 201,813 $ 81,098 $ 6,987 $ 11,361 $ 301,259 Beauty + Home 152,412 94,349 29,893 23,132 299,786 Food + Beverage 27,841 54,478 6,489 9,452 98,260 Total $ 382,066 $ 229,925 $ 43,369 $ 43,945 $ 699,305 For the Six Months Ended June 30, 2021 Segment Europe Domestic Latin Asia Total Pharma $ 420,167 $ 182,822 $ 10,664 $ 25,522 $ 639,175 Beauty + Home 381,611 202,486 73,224 49,871 707,192 Food + Beverage 60,904 139,037 21,138 20,340 241,419 Total $ 862,682 $ 524,345 $ 105,026 $ 95,733 $ 1,587,786 For the Six Months Ended June 30, 2020 Segment Europe Domestic Latin Asia Total Pharma $ 391,943 $ 172,063 $ 13,566 $ 20,883 $ 598,455 Beauty + Home 339,362 176,194 66,074 42,716 624,346 Food + Beverage 56,610 112,068 14,523 14,856 198,057 Total $ 787,915 $ 460,325 $ 94,163 $ 78,455 $ 1,420,858 We perform our obligations under a contract with a customer by transferring goods and/or services in exchange for consideration from the customer. The timing of performance will sometimes differ from the timing of the receipt of the associated consideration from the customer, thus resulting in the recognition of a contract asset or a contract liability. We recognize a contract asset when we transfer control of goods or services to a customer prior to invoicing for the related performance obligation. The contract asset is transferred to accounts receivable when the product is shipped and invoiced to the customer. We recognize a contract liability if the customer's payment of consideration precedes the entity's performance. The opening and closing balances of our contract asset and contract liabilities are as follows: Balance as of December 31, 2020 Balance as of June 30, 2021 Increase/ Contract asset (current) $ 16,109 $ 20,864 $ 4,755 Contract liability (current) 87,188 101,299 14,111 Contract liability (long-term) 21,584 23,129 1,545 The differences in the opening and closing balances of our contract asset and contract liabilities are primarily the result of timing differences between our performance and the customer’s payment. The total amount of revenue recognized during the current year against contract liabilities is $49.9 million, including $29.8 million relating to contract liabilities at the beginning of the year. Current contract assets and long-term contract assets are included within the Prepaid and Other and Miscellaneous assets, respectively, while current contract liabilities and long-term contract liabilities are included within Accounts Payable, Accrued and Other Liabilities and Deferred and Other Non-current Liabilities, respectively, within our Condensed Consolidated Balance Sheets. Determining the Transaction Price In most cases, the transaction price for each performance obligation is stated in the contract. In determining the variable amounts of consideration within the transaction price (such as volume-based customer rebates), we include an estimate of the expected amount of consideration as revenue. We apply the expected value method based on all of the information (historical, current, and forecast) that is reasonably available and identify reasonable estimates based on this information. We apply the method consistently throughout the contract when estimating the effect of an uncertainty on the amount of variable consideration to which we will be entitled. Product Sales We primarily manufacture and sell drug delivery, dispensing, sealing and active material science solutions. The amount of consideration is typically fixed for customers. At the time of delivery, the customer is invoiced the agreed-upon price. Revenue from product sales is typically recognized upon manufacture or shipment, when control of the goods transfers to the customer. To determine when the control transfers, we typically assess, among other things, the shipping terms of the contract, shipping being one of the indicators of transfer of control. For a majority of product sales, control of the goods transfers to the customer at the time of shipment of the goods. Once the goods are shipped, we are precluded from redirecting the shipment to another customer. Therefore, our performance obligation is satisfied at the time of shipment. For sales in which control transfers upon delivery, shipping and/or handling costs that occur before the customer obtains control of the goods are deemed to be fulfillment activities and are accounted for as fulfillment costs and revenue is recorded upon final delivery to the customer location. We have elected to account for shipping and handling costs that occur after the customer has obtained control of a good as fulfillment costs rather than as a promised service. We do not have any material significant payment terms as payment is typically received shortly after the point of sale. There also exist instances where we manufacture highly customized products that have no alternative use to us and for which we have an enforceable right to payment for performance completed to date. For these products, we transfer control and recognize revenue over time by measuring progress towards completion using the Output Method based on the number of products produced. As we normally make our products to a customer’s order, the time between production and shipment of our products is typically within a few weeks. We believe this measurement provides a faithful depiction of the transfer of goods as the costs incurred reflect the value of the products produced. As a part of our customary business practice, we offer a standard warranty that the products will materially comply with the technical specifications and will be free from material defects. Because such warranties are not sold separately, do not provide for any service beyond a guarantee of a product’s initial specifications, and are not required by law, there is no revenue deferral for these types of warranties. Tooling Sales We also build or contract for molds and other tools (collectively defined as “tooling”) necessary to produce our products. As with product sales, we recognize revenue when control of the tool transfers to the customer. If the tooling is highly customized with no alternative use to us and we have an enforceable right to payment for performance completed to date, we transfer control and recognize revenue over time by measuring progress towards completion using the Input Method based on costs incurred relative to total estimated costs to completion. Otherwise, revenue for the tooling is recognized at the point in time when the customer approves the tool. We do not have any material significant payment terms as payment is typically either received during the mold-build process or shortly after completion. In certain instances, we offer extended warranties on our tools above and beyond the normal standard warranties. We normally receive payment at the inception of the contract and recognize revenue over the term of the contract. We do not have any material extended warranties as of June 30, 2021 or December 31, 2020. Service Sales We also provide services to our pharmaceutical customers. As with product sales, we recognize revenue based on completion of each performance obligation of the service contract. Contract Costs We do not incur significant costs to obtain or fulfill revenue contracts. Credit Risk We are exposed to credit losses primarily through our product sales, tooling sales and services to our customers. We assess each customer’s ability to pay for the products we sell by conducting a credit review. The credit review considers our expected billing exposure and timing for payment and the customer’s established credit rating or our assessment of the customer’s creditworthiness based on our analysis of their financial statements when a credit rating is not available. We also consider contract terms and conditions, country and political risks, and business strategy in our evaluation. A credit limit is established for each customer based on the outcome of this review. We monitor our ongoing credit exposure through active review of customer balances against contract terms and due dates. Our activities include timely account reconciliation, dispute resolution and payment confirmation. We may employ collection agencies and legal counsel to pursue recovery of defaulted receivables. Current uncertainty in credit and market conditions due to the COVID-19 pandemic may slow our collection efforts if customers experience significant difficulty accessing credit and paying their obligations, which may lead to higher than normal accounts receivable and increased CECL charges.

INVENTORIES

INVENTORIES	6 Months Ended
	Jun. 30, 2021
Inventory Disclosure [Abstract]
INVENTORIES	INVENTORIES Inventories, by component net of reserves, consisted of: June 30, December 31, Raw materials $ 134,582 $ 116,029 Work in process 135,695 115,870 Finished goods 159,163 147,480 Total $ 429,440 $ 379,379

GOODWILL AND OTHER INTANGIBLE A

GOODWILL AND OTHER INTANGIBLE ASSETS	6 Months Ended
	Jun. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
GOODWILL AND OTHER INTANGIBLE ASSETS	GOODWILL AND OTHER INTANGIBLE ASSETS The changes in the carrying amount of goodwill by reporting segment since December 31, 2020 are as follows: Pharma Beauty + Food + Corporate Total Goodwill $ 436,731 $ 333,111 $ 128,679 $ 1,615 $ 900,136 Accumulated impairment losses — — — (1,615) (1,615) Balance as of December 31, 2020 $ 436,731 $ 333,111 $ 128,679 $ — $ 898,521 Foreign currency exchange effects (7,427) (3,167) (186) — (10,780) Goodwill $ 429,304 $ 329,944 $ 128,493 $ 1,615 $ 889,356 Accumulated impairment losses — — — (1,615) (1,615) Balance as of June 30, 2021 $ 429,304 $ 329,944 $ 128,493 $ — $ 887,741 The table below shows a summary of intangible assets as of June 30, 2021 and December 31, 2020. June 30, 2021 December 31, 2020 Weighted Average Amortization Period (Years) Gross Accumulated Net Gross Accumulated Net Amortized intangible assets: Patents 13.8 $ 2,822 $ (1,465) $ 1,357 $ 2,861 $ (1,477) $ 1,384 Acquired technology 12.2 110,171 (41,264) 68,907 111,854 (36,943) 74,911 Customer relationships 13.5 284,613 (67,039) 217,574 286,644 (56,714) 229,930 Trademarks and trade names 6.8 45,653 (20,286) 25,367 46,174 (17,437) 28,737 License agreements and other 38.3 15,220 (6,410) 8,810 19,208 (9,861) 9,347 Total intangible assets 13.4 $ 458,479 $ (136,464) $ 322,015 $ 466,741 $ (122,432) $ 344,309 Aggregate amortization expense for the intangible assets above for the quarters ended June 30, 2021 and 2020 was $9,811 and $12,320, respectively. Aggregate amortization expense for the intangible assets above for the six months ended June 30, 2021 and 2020 was $19,622 and $20,334, respectively. Future estimated amortization expense for the years ending December 31 is as follows: 2021 $ 19,989 (remaining estimated amortization for 2021) 2022 38,319 2023 38,236 2024 35,097 2025 and thereafter 190,374 Future amortization expense may fluctuate depending on changes in foreign currency rates. The estimates for amortization expense noted above are based upon foreign exchange rates as of June 30, 2021.

INCOME TAXES

INCOME TAXES	6 Months Ended
	Jun. 30, 2021
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES The tax provision for interim periods is determined using the estimated annual effective consolidated tax rate, based on the current estimate of full-year earnings and related estimated full year-taxes, adjusted for the impact of discrete quarterly items. The effective tax rate for the three months ended June 30, 2021 and 2020, respectively, was 25.6% and 31.0%. The lower reported effective tax rate for the three months ended June 30, 2021 reflects additional tax benefits from employee stock-based compensation and a more favorable mix of earnings. The effective tax rate for the six months ended June 30, 2021 and 2020, respectively, was 20.5% and 30.0%. The effective tax rate for the six months ended June 30, 2021 reflects additional tax benefits from employee stock-based compensation and a more favorable mix of earnings.

DEBT

DEBT	6 Months Ended
	Jun. 30, 2021
Debt Disclosure [Abstract]
DEBT	DEBT Notes Payable, Revolving Credit Facility and Overdrafts At June 30, 2021 and December 31, 2020, our notes payable, revolving credit facility and overdrafts consisted of the following: June 30, December 31, Notes payable 0.0% $ — $ 200 Revolving credit facility 1.45% — 52,000 Overdrafts 4.15% to 6.70% 2,965 — $ 2,965 $ 52,200 On June 30, 2021, we entered into an amended and restated multi-currency revolving credit facility (the "revolving credit facility") to replace the existing facility (the "prior credit facility") maturing July 2022 and to amend and restate the unsecured term loan facility extended to our wholly-owned UK subsidiary under the prior credit facility (as amended, the "amended term facility"). The revolving credit facility matures in June 2026, subject to a maximum of two one-year extensions in certain circumstances, and provides for unsecured financing of up to $600 million available in the U.S. and to our wholly-owned UK subsidiary. The amended term facility matures in July 2022. The revolving credit facility can be drawn in various currencies including USD, EUR, GBP, and CHF to the equivalent of $600 million, which may be increased by up to $300 million subject to the satisfaction of certain conditions. As of June 30, 2021, no balance was utilized under the revolving credit facility and $112 million remained outstanding under the amended term facility. As of December 31, 2020, under our prior credit facility, we utilized $52.0 million under the U.S. revolving facility and no balance was utilized under the euro-based revolving credit facility. There are no compensating balance requirements associated with our revolving credit facility. Each borrowing under the revolving credit facility will bear interest at rates based on LIBOR (in the case of USD), EURIBOR (in the case of EUR), SONIA (in the case of GBP), SARON (in the case of CHF), prime rates or other similar rates, in each case plus an applicable margin. The revolving credit facility provides mechanics relating to a transition away from LIBOR (in the case of USD) and the designated benchmark rates for other available currencies and the replacement of any such applicable benchmark by a replacement alternative benchmark rate or mechanism for loans made in the applicable currency. A facility fee on the total amount of the revolving credit facility is also payable quarterly, regardless of usage. The applicable margins for borrowings under the revolving credit facility and the facility fee percentage may change from time to time depending on changes in our consolidated leverage ratio. In October 2020, we entered into an unsecured money market borrowing arrangement to provide short term financing of up to $30 million that is available in the U.S. No borrowing on this facility is permitted over a quarter end date. As such, no balance was utilized under this arrangement as of June 30, 2021 or December 31, 2020. Long-Term Obligations At June 30, 2021 and December 31, 2020, our long-term obligations consisted of the following: June 30, 2021 December 31, 2020 Notes payable 0.00% – 10.91%, due in monthly and annual installments through 2028 $ 17,754 $ 14,002 Senior unsecured notes 3.2%, due in 2022 75,000 75,000 Senior unsecured debts 1.4% USD floating swapped to 1.36% EUR fixed, equal annual installments through 2022 112,000 112,000 Senior unsecured notes 3.5%, due in 2023 125,000 125,000 Senior unsecured notes 1.0%, due in 2023 118,590 122,100 Senior unsecured notes 3.4%, due in 2024 50,000 50,000 Senior unsecured notes 3.5%, due in 2024 100,000 100,000 Senior unsecured notes 1.2%, due in 2024 237,180 244,200 Senior unsecured notes 3.6%, due in 2025 125,000 125,000 Senior unsecured notes 3.6%, due in 2026 125,000 125,000 Finance Lease Liabilities 32,021 30,025 Unamortized debt issuance costs (1,374) (1,663) $ 1,116,171 $ 1,120,664 Current maturities of long-term obligations (67,243) (65,666) Total long-term obligations $ 1,048,928 $ 1,054,998 The aggregate long-term maturities, excluding finance lease liabilities, which are disclosed in Note 7, due annually from the current balance sheet date for the next five years are: Year One $ 63,069 Year Two 136,740 Year Three 347,690 Year Four 287,609 Year Five 250,262 Thereafter 154 Covenants Our revolving credit facility and corporate long-term obligations require us to satisfy certain financial and other covenants including: Requirement Level at June 30, 2021 Consolidated Leverage Ratio (1) Maximum of 3.50 to 1.00 1.49 to 1.00 Consolidated Interest Coverage Ratio (1) Minimum of 3.00 to 1.00 18.93 to 1.00 ________________________________________

LEASES

LEASES	6 Months Ended
	Jun. 30, 2021
Leases [Abstract]
LEASES	LEASES We lease certain warehouse, plant and office facilities as well as certain equipment under noncancelable operating and finance leases expiring at various dates through the year 2034. Most of the operating leases contain renewal options and certain leases include options to purchase the related asset during or at the end of the lease term. Amortization expense related to finance leases is included in depreciation expense while rent expense related to operating leases is included within cost of sales and selling, research & development and administrative expenses (“SG&A”). The components of lease expense for the three and six months ended June 30, 2021 and 2020 were as follows: Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Operating lease cost $ 6,044 $ 5,841 $ 11,833 $ 11,095 Finance lease cost: Amortization of right-of-use assets $ 1,099 $ 906 $ 2,075 $ 2,105 Interest on lease liabilities 375 369 687 717 Total finance lease cost $ 1,474 $ 1,275 $ 2,762 $ 2,822 Short-term lease and variable lease costs $ 2,444 $ 2,430 $ 5,572 $ 4,878 Supplemental cash flow information related to leases was as follows: Six Months Ended June 30, 2021 2020 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 11,771 $ 11,662 Operating cash flows from finance leases 716 704 Financing cash flows from finance leases 2,337 2,545 Right-of-use assets obtained in exchange for lease obligations: Operating leases $ 4,739 $ 11,371 Finance leases 4,792 3,127
LEASES	LEASES We lease certain warehouse, plant and office facilities as well as certain equipment under noncancelable operating and finance leases expiring at various dates through the year 2034. Most of the operating leases contain renewal options and certain leases include options to purchase the related asset during or at the end of the lease term. Amortization expense related to finance leases is included in depreciation expense while rent expense related to operating leases is included within cost of sales and selling, research & development and administrative expenses (“SG&A”). The components of lease expense for the three and six months ended June 30, 2021 and 2020 were as follows: Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Operating lease cost $ 6,044 $ 5,841 $ 11,833 $ 11,095 Finance lease cost: Amortization of right-of-use assets $ 1,099 $ 906 $ 2,075 $ 2,105 Interest on lease liabilities 375 369 687 717 Total finance lease cost $ 1,474 $ 1,275 $ 2,762 $ 2,822 Short-term lease and variable lease costs $ 2,444 $ 2,430 $ 5,572 $ 4,878 Supplemental cash flow information related to leases was as follows: Six Months Ended June 30, 2021 2020 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 11,771 $ 11,662 Operating cash flows from finance leases 716 704 Financing cash flows from finance leases 2,337 2,545 Right-of-use assets obtained in exchange for lease obligations: Operating leases $ 4,739 $ 11,371 Finance leases 4,792 3,127

RETIREMENT AND DEFERRED COMPENS

RETIREMENT AND DEFERRED COMPENSATION PLANS	6 Months Ended
	Jun. 30, 2021
Retirement Benefits [Abstract]
RETIREMENT AND DEFERRED COMPENSATION PLANS	RETIREMENT AND DEFERRED COMPENSATION PLANSEffective January 1, 2021, our domestic noncontributory retirement plans were amended to provide that no individual who became an employee after December 31, 2020 could become a participant and that no employee whose employment terminated and who was rehired after December 31, 2020 may accrue benefits under the plan with respect to the period of employment which begins on the date that reemployment commences. These employees will instead be eligible for additional contribution to their defined contribution 401(k) employee savings plan. All domestic employees with hire/rehire dates prior to January 1, 2021 will still be eligible for the domestic pension plans and will still continue to accrue plan benefits after this date. Components of Net Periodic Benefit Cost: Domestic Plans Foreign Plans Three Months Ended June 30, 2021 2020 2021 2020 Service cost $ 3,941 $ 3,562 $ 2,071 $ 1,767 Interest cost 1,604 1,536 208 340 Expected return on plan assets (3,064) (2,702) (721) (631) Amortization of net loss 2,501 1,294 591 514 Amortization of prior service cost — — 44 95 Net periodic benefit cost $ 4,982 $ 3,690 $ 2,193 $ 2,085 Domestic Plans Foreign Plans Six Months Ended June 30, 2021 2020 2021 2020 Service cost $ 8,168 $ 7,139 $ 4,149 $ 3,535 Interest cost 3,215 3,523 426 680 Expected return on plan assets (6,137) (6,124) (1,444) (1,265) Amortization of net loss 5,004 2,842 1,180 1,028 Amortization of prior service cost — — 89 192 Net periodic benefit cost $ 10,250 $ 7,380 $ 4,400 $ 4,170 The components of net periodic benefit cost, other than the service cost component, are included in the line Miscellaneous, net in the Condensed Consolidated Statements of Income. EMPLOYER CONTRIBUTIONS We currently have no minimum funding requirements for our domestic and foreign plans. We contributed $1.0 million to our ongoing domestic supplemental executive retirement plan (SERP) annuity contracts during the six months ended June 30, 2021 and we do not expect additional significant payments during 2021. We have contributed approximately $2.3 million to our foreign defined benefit plans during the six months ended June 30, 2021 and do not expect additional significant contributions during 2021.

ACCUMULATED OTHER COMPREHENSIVE

ACCUMULATED OTHER COMPREHENSIVE INCOME	6 Months Ended
	Jun. 30, 2021
Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]
ACCUMULATED OTHER COMPREHENSIVE INCOME	ACCUMULATED OTHER COMPREHENSIVE INCOME Changes in Accumulated Other Comprehensive (Loss) Income by Component: Foreign Currency Defined Benefit Pension Plans Derivatives Total Balance - December 31, 2019 $ (257,124) $ (83,147) $ (1,677) $ (341,948) Other comprehensive (loss) income before reclassifications (23,134) — 1,758 (21,376) Amounts reclassified from accumulated other comprehensive income (loss) — 3,076 (1,008) 2,068 Net current-period other comprehensive (loss) income (23,134) 3,076 750 (19,308) Balance - June 30, 2020 $ (280,258) $ (80,071) $ (927) $ (361,256) Balance - December 31, 2020 $ (178,025) $ (102,322) $ (1,362) $ (281,709) Other comprehensive (loss) income before reclassifications (27,373) 442 4,066 (22,865) Amounts reclassified from accumulated other comprehensive income (loss) — 4,773 (3,257) 1,516 Net current-period other comprehensive (loss) income (27,373) 5,215 809 (21,349) Balance - June 30, 2021 $ (205,398) $ (97,107) $ (553) $ (303,058) Reclassifications Out of Accumulated Other Comprehensive (Loss) Income: Details about Accumulated Other Amount Reclassified from Accumulated Other Comprehensive Income Affected Line in the Statement Three Months Ended June 30, 2021 2020 Defined Benefit Pension Plans Amortization of net loss $ 3,092 $ 1,808 (1) Amortization of prior service cost 44 95 (1) 3,136 1,903 Total before tax (750) (463) Tax impact $ 2,386 $ 1,440 Net of tax Derivatives Changes in cross currency swap: interest component $ (6) $ (525) Interest Expense Changes in cross currency swap: foreign exchange component 1,290 3,060 Miscellaneous, net $ 1,284 $ 2,535 Net of tax Total reclassifications for the period $ 3,670 $ 3,975 Details about Accumulated Other Amount Reclassified from Accumulated Other Comprehensive Income Affected Line in the Statement Six Months Ended June 30, 2021 2020 Defined Benefit Pension Plans Amortization of net loss $ 6,184 $ 3,870 (1) Amortization of prior service cost 89 192 (1) 6,273 4,062 Total before tax (1,500) (986) Tax impact $ 4,773 $ 3,076 Net of tax Derivatives Changes in cross currency swap: interest component $ (18) $ (1,288) Interest Expense Changes in cross currency swap: foreign exchange component (3,239) 280 Miscellaneous, net $ (3,257) $ (1,008) Net of tax Total reclassifications for the period $ 1,516 $ 2,068 ______________________________________________ (1) These accumulated other comprehensive income components are included in the computation of net periodic benefit costs, net of tax. See Note 8 – Retirement and Deferred Compensation Plans for additional details.

DERIVATIVE INSTRUMENTS AND HEDG

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES	6 Months Ended
	Jun. 30, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]
DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES	DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIESWe maintain a foreign exchange risk management policy designed to establish a framework to protect the value of our non-functional currency denominated transactions from adverse changes in exchange rates. Sales of our products can be denominated in a currency different from the currency in which the related costs to produce the product are denominated. Changes in exchange rates on such inter-country sales or intercompany loans can impact our results of operations. Our policy is not to engage in speculative foreign currency hedging activities, but to minimize our net foreign currency transaction exposure, defined as firm commitments and transactions recorded and denominated in currencies other than the functional currency. We may use foreign currency forward exchange contracts, options and cross currency swaps to economically hedge these risks. For derivative instruments designated as hedges, we formally document the nature and relationships between the hedging instruments and the hedged items, as well as the risk management objectives, strategies for undertaking the various hedge transactions, and the method of assessing hedge effectiveness at inception. Quarterly thereafter, we formally assess whether the derivatives that are used in hedging transactions are highly effective in offsetting changes in the fair value or cash flows of the hedged item. Additionally, in order to designate any derivative instrument as a hedge of an anticipated transaction, the significant characteristics and expected terms of any anticipated transaction must be specifically identified, and it must be probable that the anticipated transaction will occur. All derivative financial instruments used as hedges are recorded at fair value in the Condensed Consolidated Balance Sheets (See Note 11 - Fair Value). Cash Flow Hedge For derivative instruments that are designated and qualify as cash flow hedges, the changes in fair values are recorded in accumulated other comprehensive loss and included in changes in derivative gain/loss. The changes in the fair values of derivatives designated as cash flow hedges are reclassified from accumulated other comprehensive loss to net income when the underlying hedged item is recognized in earnings. Cash flows from the settlement of derivative contracts designated as cash flow hedges offset cash flows from the underlying hedged items and are included in operating activities in the Condensed Consolidated Statements of Cash Flows. During 2017, our wholly-owned UK subsidiary borrowed $280 million in term loan borrowings under our prior credit facility. In order to mitigate the currency risk of U.S. dollar debt on a euro functional currency entity and to mitigate the risk of variability in interest rates, we entered into a EUR/USD floating-to-fixed cross currency interest rate swap in the notional amount of $280 million to effectively hedge the foreign exchange and interest rate exposure on the $280 million term loan. This EUR/USD swap agreement fixed our U.S. dollar floating-rate debt to 1.36% euro fixed-rate debt. Related to this hedge, approximately $0.6 million of loss is included in accumulated other comprehensive loss at June 30, 2021. The amount expected to be recognized into earnings during the next 12 months related to the interest component of our cross currency swap based on prevailing foreign exchange and interest rates at June 30, 2021 is a gain of $0.8 million. The amount expected to be recognized into earnings during the next 12 months related to the foreign exchange component of our cross currency swap is dependent on fluctuations in currency exchange rates. As of June 30, 2021, the fair value of the cross currency swap was a $4.1 million liability. The swap contract expires on July 20, 2022. Hedge of Net Investments in Foreign Operations A significant number of our operations are located outside of the United States. Because of this, movements in exchange rates may have a significant impact on the translation of the financial condition and results of operations of our foreign subsidiaries. A weakening U.S. dollar relative to foreign currencies has an additive translation effect on our financial condition and results of operations. Conversely, a strengthening U.S. dollar has a dilutive effect. In some cases, we maintain debt in these subsidiaries to offset the net asset exposure. We do not otherwise actively manage this risk using derivative financial instruments. In the event we plan on a full or partial liquidation of any of our foreign subsidiaries where our net investment is likely to be monetized, we will consider hedging the currency exposure associated with such a transaction. Other As of June 30, 2021, we have recorded the fair value of foreign currency forward exchange contracts of $30 thousand in prepaid and other and $1.5 million in accounts payable, accrued and other liabilities on the balance sheet. All forward exchange contracts outstanding as of June 30, 2021 had an aggregate notional contract amount of $49.9 million. Fair Value of Derivative Instruments in the Condensed Consolidated Balance Sheets as of June 30, 2021 and December 31, 2020 June 30, 2021 December 31, 2020 Balance Sheet Location Derivatives Designated as Hedging Instruments Derivatives not Designated as Hedging Instruments Derivatives Designated as Hedging Instruments Derivatives not Designated as Hedging Instruments Derivative Assets Foreign Exchange Contracts Prepaid and other $ — $ 30 $ — $ 322 $ — $ 30 $ — $ 322 Derivative Liabilities Foreign Exchange Contracts Accounts payable, accrued and other liabilities $ — $ 1,526 $ — $ 146 Cross Currency Swap Contract (1) Accounts payable, accrued and other liabilities 4,056 — 8,309 — $ 4,056 $ 1,526 $ 8,309 $ 146 __________________________ (1) This cross currency swap contract is composed of both an interest component and a foreign exchange component. The Effect of Cash Flow Hedge Accounting on Accumulated Other Comprehensive Income (Loss) for the Three Months Ended June 30, 2021 and 2020 Derivatives in Cash Flow Hedging Amount of Gain (Loss) Location of (Loss) Amount of Gain (Loss) Total Amount of Affected Income Statement Line Item 2021 2020 2021 2020 Cross currency swap contract: Interest component $ 295 $ (208) Interest expense $ 6 $ 525 $ (7,175) Foreign exchange component (1,290) (3,060) Miscellaneous, net (1,290) (3,060) (2,028) $ (995) $ (3,268) $ (1,284) $ (2,535) The Effect of Cash Flow Hedge Accounting on Accumulated Other Comprehensive Income (Loss) for the Six Months Ended June 30, 2021 and 2020 Derivatives in Cash Flow Hedging Amount of Gain (Loss) Location of (Loss) Amount of Gain (Loss) Total Amount of Affected Income Statement Line Item 2021 2020 2021 2020 Cross currency swap contract: Interest component $ 827 $ 2,038 Interest expense $ 18 $ 1,288 $ (14,590) Foreign exchange component 3,239 (280) Miscellaneous, net 3,239 (280) (2,991) $ 4,066 $ 1,758 $ 3,257 $ 1,008 The Effect of Derivatives Not Designated as Hedging Instruments on the Condensed Consolidated Statements of Income for the Three Months Ended June 30, 2021 and 2020 Derivatives Not Designated Location of (Loss) Gain Recognized Amount of (Loss) Gain 2021 2020 Foreign Exchange Contracts Other (Expense) Income: $ (1,176) $ (940) $ (1,176) $ (940) The Effect of Derivatives Not Designated as Hedging Instruments on the Condensed Consolidated Statements of Income for the Six Months Ended June 30, 2021 and 2020 Derivatives Not Designated Location of (Loss) Gain Recognized Amount of (Loss) Gain 2021 2020 Foreign Exchange Contracts Other (Expense) Income: $ (1,689) $ 807 $ (1,689) $ 807 Gross Amounts Offset in the Statement of Financial Position Net Amounts Presented in the Statement of Financial Position Gross Amounts not Offset in the Statement of Financial Position Gross Amount Financial Instruments Cash Collateral Received Net Amount Description June 30, 2021 Derivative Assets $ 30 — $ 30 — — $ 30 Total Assets $ 30 — $ 30 — — $ 30 Derivative Liabilities $ 5,582 — $ 5,582 — — $ 5,582 Total Liabilities $ 5,582 — $ 5,582 — — $ 5,582 December 31, 2020 Derivative Assets $ 322 — $ 322 — — $ 322 Total Assets $ 322 — $ 322 — — $ 322 Derivative Liabilities $ 8,455 — $ 8,455 — — $ 8,455 Total Liabilities $ 8,455 — $ 8,455 — — $ 8,455

FAIR VALUE

FAIR VALUE	6 Months Ended
	Jun. 30, 2021
Fair Value Disclosures [Abstract]
FAIR VALUE	FAIR VALUE Authoritative guidelines require the categorization of assets and liabilities into three levels based upon the assumptions (inputs) used to price the assets or liabilities. Level 1 provides the most reliable measure of fair value, whereas Level 3 generally requires significant management judgment. The three levels are defined as follows: • Level 1: Unadjusted quoted prices in active markets for identical assets and liabilities. • Level 2: Observable inputs other than those included in Level 1. For example, quoted prices for similar assets or liabilities in active markets or quoted prices for identical assets or liabilities in inactive markets. • Level 3: Unobservable inputs reflecting management’s own assumptions about the inputs used in pricing the asset or liability. As of June 30, 2021, the fair values of our financial assets and liabilities were categorized as follows: Total Level 1 Level 2 Level 3 Assets Investment in equity securities (1) $ 20,595 $ 20,595 $ — $ — Foreign exchange contracts (2) 30 — 30 — Total assets at fair value $ 20,625 $ 20,595 $ 30 $ — Liabilities Foreign exchange contracts (2) $ 1,526 $ — $ 1,526 $ — Cross currency swap contract (2) 4,056 — 4,056 — Contingent consideration obligation 33,090 — — 33,090 Total liabilities at fair value $ 38,672 $ — $ 5,582 $ 33,090 As of December 31, 2020, the fair values of our financial assets and liabilities were categorized as follows: Total Level 1 Level 2 Level 3 Assets Foreign exchange contracts (2) $ 322 $ — $ 322 $ — Total assets at fair value $ 322 $ — $ 322 $ — Liabilities Foreign exchange contracts (2) $ 146 $ — $ 146 $ — Cross currency swap contract (2) 8,309 — 8,309 — Contingent consideration obligation 31,140 — — 31,140 Total liabilities at fair value $ 39,595 $ — $ 8,455 $ 31,140 ________________________________________________ (1) Investment in PureCycle Technologies (PCT). See Note 18 - Investment in Equity Securities for discussion of this investment. (2) Market approach valuation technique based on observable market transactions of spot and forward rates. The carrying amounts of our other current financial instruments such as cash and equivalents, accounts and notes receivable, notes payable and current maturities of long-term obligations approximate fair value due to the short-term maturity of the instruments. We consider our long-term obligations a Level 2 liability and utilize the market approach valuation technique based on interest rates that are currently available to us for issuance of debt with similar terms and maturities. The estimated fair value of our long-term obligations was $1.1 billion as of June 30, 2021 and $1.1 billion as of December 31, 2020. As discussed in Note 19 - Acquisitions of our Annual Report on Form 10-K for the year ended December 31, 2020, we have a contingent consideration obligation to the selling equity holders of: – Fusion Packaging, Inc. ("Fusion") in connection with the acquisition of 100% of the equity interests of Fusion (the "Fusion Acquisition") based on 2022 cumulative performance targets, and – Noble International Holdings, Inc., Genia Medical, Inc. and JBCB Holdings, LLC (collectively referred to as "Noble") in connection with the acquisition of 100% of the equity interests of Noble (the "Noble Acquisition") based on 2024 cumulative performance targets. We consider these obligations Level 3 liabilities and have estimated the aggregate fair value for these contingent consideration arrangements as follows: June 30, 2021 December 31, 2020 Fusion Acquisition $ 28,010 $ 26,910 Noble Acquisition 5,080 4,230 $ 33,090 $ 31,140 Changes in the fair value of these obligations are recorded within selling, research & development and administrative expenses in our Condensed Consolidated Statements of Income. Significant changes to the inputs, as noted above, can result in a significantly higher or lower fair value measurement. The following table provides a summary of changes in our Level 3 fair value measurements: Balance, December 31, 2020 $ 31,140 Increase in fair value recorded in earnings 1,950 Balance, June 30, 2021 $ 33,090

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	6 Months Ended
	Jun. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES In the normal course of business, we are subject to a number of lawsuits and claims both actual and potential in nature. While management believes the resolution of these claims and lawsuits will not have a material adverse effect on our financial position, our results of operations or cash flows, claims and legal proceedings are subject to inherent uncertainties, and unfavorable outcomes could occur and could include amounts in excess of any accruals which management has established. Were such unfavorable final outcomes to occur, it is possible that they could have a material adverse effect on our financial position, results of operations and cash flows. Under our Certificate of Incorporation, we have agreed to indemnify our officers and directors for certain events or occurrences while the officer or director is, or was, serving at our request in such capacity. The maximum potential amount of future payments we could be required to make under these indemnification agreements is unlimited; however, we have a directors and officers liability insurance policy that covers a portion of our exposure. As a result of our insurance policy coverage, we believe the estimated fair value of these indemnification agreements is minimal. We have no liabilities recorded for these agreements as of June 30, 2021 and December 31, 2020. In March 2017, the Supreme Court of Brazil issued a decision that a certain state value added tax should not be included in the calculation of federal gross receipts taxes. The decision reduces our gross receipts tax in Brazil prospectively and retrospectively. In May 2021, the Supreme Court of Brazil issued a judgment establishing rules for the refund of amounts paid in excess based on the calculation methodology to be applied. In June 2021 and June 2020, we received favorable court decisions of $1.6 million and $0.7 million, respectively, for the retrospective right to recover part of our claim. These amounts were recorded in cost of sales. If the Supreme Court of Brazil grants full retrospective recovery, we estimate remaining potential recoveries of approximately $3 million to $6 million, including interest. Due to uncertainties around our remaining court recovery claims, we have not recorded any further amounts relating to the retrospective nature of this matter. In December 2019, tax authorities in Brazil notified us of a tax assessment of approximately $6.1 million, including interest and penalties of $2.3 million and $0.8 million, respectively, relating to differences in tax classification codes used for import duties for the period from January 2015 to August 2018. We are vigorously contesting the assessment, including interest and penalties, and have filed an administrative defense appeal in December 2019. In June 2020, an unfavorable decision was issued on the first administrative defense appeal. We filed a second administrative defense appeal in August 2020. We still believe we have a strong defense. Due to uncertainty in the amount of assessment and the timing of our appeal, no liability is recorded as of June 30, 2021.

STOCK REPURCHASE PROGRAM

STOCK REPURCHASE PROGRAM	6 Months Ended
	Jun. 30, 2021
Equity [Abstract]
STOCK REPURCHASE PROGRAM	STOCK REPURCHASE PROGRAM On April 18, 2019, we announced a share repurchase authorization of up to $350 million of common stock. This authorization replaces previous authorizations and has no expiration date. We may repurchase shares through the open market, privately negotiated transactions or other programs, subject to market conditions. During the three and six months ended June 30, 2021 and 2020, we did not repurchase any shares. As of June 30, 2021, there was $278.5 million of authorized share repurchases available to us.

STOCK-BASED COMPENSATION

STOCK-BASED COMPENSATION	6 Months Ended
	Jun. 30, 2021
Share-based Payment Arrangement [Abstract]
STOCK-BASED COMPENSATION	STOCK-BASED COMPENSATIONWe issue restricted stock units (“RSUs”), which consist of time-based and performance-based awards, to employees under stock awards plans approved by stockholders. In addition, RSUs are issued to non-employee directors under a Restricted Stock Unit Award Agreement for Directors pursuant to the Company’s 2018 Equity Incentive Plan. RSUs granted to employees vest according to a specified performance period and/or vesting period. Time-based RSUs generally vest over three years. Performance-based RSUs vest at the end of the specified performance period, generally three years, assuming required performance or market vesting conditions are met. Performance-based RSUs have one of two vesting conditions: (1) based on our internal financial performance metrics and (2) based on our total shareholder return (“TSR”) relative to total shareholder returns of an industrial peer group. At the time of vesting, the vested shares of common stock are issued in the employee’s name. In addition, RSU awards are generally net settled (shares are withheld to cover the employee tax obligation). RSUs granted to directors are only time-based and generally vest over one year. The fair value of both time-based RSUs and performance-based RSUs pertaining to internal performance metrics is determined using the closing price of our common stock on the grant date. The fair value of performance-based RSUs pertaining to TSR is estimated using a Monte Carlo simulation. Inputs and assumptions used to calculate the fair value are shown in the table below. The fair value of these RSUs is expensed over the vesting period using the straight-line method or using the graded vesting method when an employee becomes eligible to retain the award at retirement. Six Months Ended June 30, 2021 2020 Fair value per stock award $ 171.63 $ 94.98 Grant date stock price $ 141.59 $ 83.93 Assumptions: Aptar's stock price expected volatility 21.40 % 23.80 % Expected average volatility of peer companies 50.00 % 48.50 % Correlation assumption 58.10 % 63.50 % Risk-free interest rate 0.32 % 0.31 % Dividend yield assumption 1.02 % 1.72 % A summary of RSU activity as of June 30, 2021 and changes during the six month period then ended is presented below: Time-Based RSUs Performance-Based RSUs Units Weighted Average Units Weighted Average Nonvested at January 1, 2021 576,198 $ 92.47 590,064 $ 100.27 Granted 140,316 139.25 169,974 152.51 Vested (134,808) 91.39 (71,994) 128.70 Forfeited (3,244) 99.42 (31,872) 91.67 Nonvested at June 30, 2021 578,462 $ 107.45 656,172 $ 111.10 Included in the activity for the six months ended June 30, 2021 time-based RSUs are 10,007 units granted to non-employee directors and 12,379 units vested related to non-employee directors. Six Months Ended June 30, 2021 2020 Compensation expense $ 21,579 $ 16,353 Fair value of units vested 20,778 10,696 Intrinsic value of units vested 28,259 12,821 The actual tax benefit realized for the tax deduction from RSUs was approximately $4.0 million in the six months ended June 30, 2021. As of June 30, 2021, there was $61.3 million of total unrecognized compensation cost relating to RSU awards which is expected to be recognized over a weighted-average period of 2 years. Historically we issued stock options to our employees and non-employee directors. Beginning in 2019, we no longer issue stock options. Stock options were awarded with the exercise price equal to the market price on the date of grant and generally vest over three years and expire 10 years after grant. For stock option grants, we used historical data to estimate expected life and volatility. A summary of option activity under our stock plans during the six months ended June 30, 2021 is presented below: Stock Awards Plans Director Stock Option Plans Options Weighted Average Options Weighted Average Outstanding, January 1, 2021 3,998,047 $ 70.28 99,200 $ 60.80 Granted — — — — Exercised (816,058) 64.74 (47,500) 57.40 Forfeited or expired (10,153) 75.46 — — Outstanding at June 30, 2021 3,171,836 $ 71.69 51,700 $ 63.91 Exercisable at June 30, 2021 3,171,836 $ 71.69 51,700 $ 63.91 Weighted-Average Remaining Contractual Term (Years): Outstanding at June 30, 2021 4.5 2.6 Exercisable at June 30, 2021 4.5 2.6 Aggregate Intrinsic Value: Outstanding at June 30, 2021 $ 221,908 $ 4,019 Exercisable at June 30, 2021 $ 221,908 $ 4,019 Intrinsic Value of Options Exercised During the Six Months Ended: June 30, 2021 $ 63,407 $ 4,248 June 30, 2020 $ 26,027 $ 1,973 Six Months Ended June 30, 2021 2020 Compensation expense (included in SG&A) $ 185 $ 1,051 Compensation expense (included in Cost of sales) 42 200 Compensation expense, Total $ 227 $ 1,251 Compensation expense, net of tax 174 951 Grant date fair value of options vested 2,421 7,565 The reduction in stock option expense is due to our move to RSUs as discussed above. Cash received from option exercises was approximately $53.0 million during the six months ended June 30, 2021. The actual tax benefit realized for the tax deduction from option exercises was approximately $15.0 million and $6.4 million in the six months ended June 30, 2021 and 2020, respectively. As of June 30, 2021, there is no remaining valuation of stock option awards to be expensed in future periods.

EARNINGS PER SHARE

EARNINGS PER SHARE	6 Months Ended
	Jun. 30, 2021
Earnings Per Share [Abstract]
EARNINGS PER SHARE	EARNINGS PER SHAREBasic net income per share is calculated by dividing net income attributable to Aptar by the weighted-average number of common shares outstanding during the period. Diluted net income per share is calculated by dividing the net income attributable to Aptar by the weighted-average number of common and common equivalent shares outstanding during the applicable period. The difference between basic and diluted earnings per share is attributable to stock-based compensation awards. Stock-based compensation awards for which total employee proceeds exceed the average market price over the applicable period would have an antidilutive effect on earnings per share, and accordingly, are excluded from the calculation of diluted earnings per share. The reconciliation of basic and diluted earnings per share for the three and six months ended June 30, 2021 and 2020 is as follows: Three Months Ended June 30, 2021 June 30, 2020 Diluted Basic Diluted Basic Consolidated operations Income available to common stockholders $ 55,276 $ 55,276 $ 41,839 $ 41,839 Average equivalent shares Shares of common stock 65,818 65,818 64,262 64,262 Effect of dilutive stock-based compensation Stock options 1,727 — 1,661 — Restricted stock 541 — 461 — Total average equivalent shares 68,086 65,818 66,384 64,262 Net income per share $ 0.81 $ 0.84 $ 0.63 $ 0.65 Six Months Ended June 30, 2021 June 30, 2020 Diluted Basic Diluted Basic Consolidated operations Income available to common stockholders $ 139,228 $ 139,228 $ 97,092 $ 97,092 Average equivalent shares Shares of common stock 65,525 65,525 64,135 64,135 Effect of dilutive stock-based compensation Stock options 1,804 — 1,734 — Restricted stock 540 — 377 — Total average equivalent shares 67,869 65,525 66,246 64,135 Net income per share $ 2.05 $ 2.12 $ 1.47 $ 1.51

SEGMENT INFORMATION

SEGMENT INFORMATION	6 Months Ended
	Jun. 30, 2021
Segment Reporting [Abstract]
SEGMENT INFORMATION	SEGMENT INFORMATION We are organized into three reporting segments. Operations that sell dispensing systems, drug delivery systems, sealing solutions and services to the prescription drug, consumer health care, injectables, and active material science solutions markets form the Pharma segment. Operations that sell dispensing systems and sealing solutions primarily to the beauty, personal care and home care markets form the Beauty + Home segment. Operations that sell dispensing systems and sealing solutions to the food and beverage markets form the Food + Beverage segment. The accounting policies of the segments are the same as those described in Part II, Item 8, Note 1 - Summary of Significant Accounting Policies in our Annual Report on Form 10-K for the year ended December 31, 2020. We evaluate performance of our reporting segments and allocate resources based upon Adjusted EBITDA. Adjusted EBITDA is defined as earnings before net interest, taxes, depreciation, amortization, unallocated corporate expenses, restructuring initiatives, acquisition-related costs, net investment gains and losses related to observable market price changes on equity securities and other special items. Financial information regarding our reporting segments is shown below: Three Months Ended Six Months Ended 2021 2020 2021 2020 Total Sales: Pharma $ 328,549 $ 303,885 $ 644,360 $ 603,475 Beauty + Home 366,641 306,469 720,018 636,935 Food + Beverage 125,918 99,023 242,621 199,324 Total Sales $ 821,108 $ 709,377 $ 1,606,999 $ 1,439,734 Less: Intersegment Sales: Pharma $ 3,206 $ 2,626 $ 5,185 $ 5,020 Beauty + Home 6,395 6,683 12,826 12,589 Food + Beverage 475 763 1,202 1,267 Total Intersegment Sales $ 10,076 $ 10,072 $ 19,213 $ 18,876 Net Sales: Pharma $ 325,343 $ 301,259 $ 639,175 $ 598,455 Beauty + Home 360,246 299,786 707,192 624,346 Food + Beverage 125,443 98,260 241,419 198,057 Net Sales $ 811,032 $ 699,305 $ 1,587,786 $ 1,420,858 Adjusted EBITDA (1): Pharma $ 105,979 $ 104,099 $ 214,463 $ 212,441 Beauty + Home 37,910 23,974 73,266 58,221 Food + Beverage 19,626 17,785 39,616 33,192 Corporate & Other, unallocated (15,959) (9,279) (27,566) (23,107) Acquisition-related costs (2) (2,434) (3,592) (2,434) (5,866) Restructuring Initiatives (3) (4,876) (7,331) (8,548) (12,170) Net investment (loss) gain (4) (1,611) — 15,198 — Depreciation and amortization (57,790) (56,429) (115,228) (107,235) Interest Expense (7,175) (8,734) (14,590) (17,122) Interest Income 624 175 1,005 350 Income before Income Taxes $ 74,294 $ 60,668 $ 175,182 $ 138,704 ________________________________________________ (1) We evaluate performance of our reporting segments and allocate resources based upon Adjusted EBITDA. Adjusted EBITDA is defined as earnings before net interest, taxes, depreciation, amortization, unallocated corporate expenses, restructuring initiatives, acquisition-related costs, net investment gains and losses related to observable market price changes on equity securities and other special items. (2) Acquisition-related costs include transaction costs and purchase accounting adjustments related to acquisitions and investments (see Note 17 – Acquisitions and Note 18 – Investment in Equity Securities for further details). (3) Restructuring Initiatives includes expense items for the three and six months ended June 30, 2021 and 2020 as follows (see Note 19 – Restructuring Initiatives for further details): Three Months Ended Six Months Ended 2021 2020 2021 2020 Restructuring Initiatives by Segment Pharma $ 38 $ (111) $ 73 $ (142) Beauty + Home 1,457 7,324 2,553 12,231 Food + Beverage 117 75 38 178 Corporate & Other 3,264 43 5,884 (97) Total Restructuring Initiatives $ 4,876 $ 7,331 $ 8,548 $ 12,170 (4) Net investment (loss) gain represents the change in fair value of our investment in PCT (see Note 18 – Investment in Equity Securities for further details).

ACQUISITIONS

ACQUISITIONS	6 Months Ended
	Jun. 30, 2021
Business Combinations [Abstract]
ACQUISITIONS	ACQUISITIONS Business Combinations In June 2021, we entered into exclusive negotiations to acquire 100% of the outstanding shares (the “Voluntis Acquisition”) of Voluntis. Voluntis, based in Boston, MA and Paris, France, is a pioneer in digital therapeutics. Under the terms of the contemplated transaction, Aptar would acquire from certain members of the management and certain shareholders the entirety of their shares representing approximately 64.6% of the share capital of Voluntis (on a non-diluted basis) at a price of €8.70 per share for approximately €50.8 million (approximately $61.5 million assuming a euro/USD exchange rate of 1.21). This values the full company equity (on a fully diluted basis) at approximately €78.8 million (approximately $95.3 million). Upon completion of this acquisition, Aptar will launch a mandatory cash simplified tender offer to acquire Voluntis's remaining shares for the same price of €8.70 per share (the "tender offer"). If the regulatory conditions are met upon completion of the tender offer, Aptar intends to implement a mandatory squeeze-out on the remaining outstanding shares of Voluntis on the same financial terms as those of the tender offer. The acquisition, which is subject to customary regulatory approvals and other closing conditions, the tender offer, which is subject to regulatory clearance from the French Markets Authority, and the squeeze-out are expected to be completed before the end of the fourth quarter of 2021. The purchase will be funded with available cash on hand. Subsequent to the end of the second quarter, on July 22, 2021, we signed a share purchase agreement for the Voluntis Acquisition with terms consistent with the description above. On May 25, 2021, we entered into a strategic definitive agreement to acquire 80% of the equity interests (the "Hengyu Acquisition") in Weihai Hengyu Medical Products Co., Ltd. ("Hengyu"). Hengyu, a leading Chinese manufacturer of elastomeric and plastic components used in injectable drug delivery, is based in Weihai, China and has an enterprise value of $77 million. The closing of the transaction, expected during the third quarter of 2021, is subject to customary regulatory approvals and other closing conditions. Under the terms of the deal, we have the option to acquire the remaining 20% of Hengyu after a 5-year lock up period. The purchase will be funded with available cash on hand. On April 1, 2020, we completed the Fusion Acquisition for a purchase price of approximately $163.8 million (net of $1.0 million of cash acquired), which was funded by a draw on our prior credit facility and cash on hand. Fusion, based in Dallas, TX, is a global leader in the design, engineering and distribution of luxury packaging for the beauty industry. As part of the Fusion Acquisition, we are also obligated to pay to the selling equity holders of Fusion certain contingent consideration based on 2022 cumulative financial performance metrics as defined in the purchase agreement. Based on a projection as of the acquisition date, we estimated the aggregate fair value for this contingent consideration arrangement to be $19.1 million utilizing a Black-Scholes valuation model. During the fourth quarter of 2020, a $3.6 million fair value true-up was recorded as an adjustment to the opening balance of goodwill and contingent liability. As of June 30, 2021, we have estimated the aggregate fair value for this contingent consideration arrangement to be $28.0 million. As of the acquisition date, $5.7 million was held in restricted cash pending the finalization of a working capital adjustment and indemnity escrow. During the third quarter of 2020, $2.0 million related to the working capital escrow was released from restriction, resulting in a refund from seller of $294 thousand and a corresponding decrease to our purchase price and associated goodwill balance. During the second quarter of 2021, the remaining restricted cash was released. The results of Fusion's operations have been included in the Condensed Consolidated Financial Statements within our Beauty + Home segment since the date of acquisition. The following table summarizes the assets acquired and liabilities assumed in the Fusion Acquisition as of the acquisition date at estimated fair value. 2020 Assets Cash and equivalents $ 1,010 Accounts receivable 4,380 Inventories 386 Prepaid and other 1,090 Property, plant and equipment 2,885 Goodwill 103,130 Intangible assets 79,900 Operating lease right-of-use assets 4,744 Other miscellaneous assets 65 Liabilities Accounts payable, accrued and other liabilities 5,641 Deferred income taxes — Operating lease liabilities 4,207 Deferred and other non-current liabilities 322 Net assets acquired $ 187,420 The following table is a summary of the fair value estimates of the acquired identifiable intangible assets and weighted-average useful lives as of the acquisition date: 2020 Weighted-Average Useful Life (in Years) Estimated Fair Value of Assets Acquired technology 4 $ 4,600 Customer relationships 13 62,300 Trademarks and trade names 4 10,300 License agreements and other 0.25 2,700 Total $ 79,900 Goodwill in the amount of $103.1 million was recorded related to the Fusion Acquisition which is included in the Beauty + Home segment. Goodwill is calculated as the excess of the consideration transferred over the net assets acquired and represents the estimated future economic benefits arising from other assets acquired that could not be individually identified and separately recognized. Goodwill largely consists of unique relationships, brand equity and proprietary technology that has been established creating niches such as turnkey solutions for the beauty market related to the Fusion Acquisition as well as the abilities of acquired companies to maintain their competitive advantage from a technical viewpoint. Goodwill will not be amortized, but will be tested for impairment at least annually. For 2020 acquisitions, goodwill of $80.6 million is deductible for tax purposes. Asset Acquisition On October 16, 2020, we completed our acquisition of the assets of Cohero Health, Inc. ("Cohero Health") for $2.4 million. The net assets acquired and the results of Cohero Health's operations have been included in the Condensed Consolidated Financial Statements within our Pharma segment since the date of acquisition. Based in New York, Cohero Health develops innovative digital tools and technologies to improve respiratory care, reduce avoidable costs and optimize medication utilization.

INVESTMENT IN EQUITY SECURITIES

INVESTMENT IN EQUITY SECURITIES	6 Months Ended
	Jun. 30, 2021
Equity Method Investments and Joint Ventures [Abstract]
INVESTMENT IN EQUITY SECURITIES	INVESTMENT IN EQUITY SECURITIES Our investment in equity securities consisted of the following: June 30, December 31, Equity Method Investments: BTY $ 33,005 $ 33,020 Sonmol 5,710 5,598 Kali Care 422 535 Desotec GmbH 943 964 Other Investments: PureCycle 20,595 5,397 Loop 2,894 2,894 Others 1,631 1,679 $ 65,200 $ 50,087 Equity method investments BTY On January 1, 2020, we acquired 49% of the equity interests in 3 related companies: Suzhou Hsing Kwang, Suqian Hsing Kwang and Suzhou BTY (collectively referred to as “BTY”) for an approximate purchase price of $32 million. We have a call option to acquire an additional 26% to 31% of BTY’s equity interests following the initial lock-up period of 5 years based on a predetermined formula. Subsequent to the second lock-up period, which ends 3 years after the initial lock-up period, we have a call option to acquire the remaining equity interests of BTY based on a predetermined formula. Additionally, the selling shareholders of BTY have a put option for the remaining equity interest to be acquired by Aptar based on a predetermined formula. The BTY entities are leading Chinese manufacturers of high quality, decorative metal components, metal-plastic sub-assemblies, and complete color cosmetics packaging solutions for the beauty industry. Sonmol On April 1, 2020, we invested $5 million to acquire 30% of the equity interests in Healthcare, Inc., Shanghai Sonmol Internet Technology Co., Ltd. and its subsidiary, Shanghai Sonmol Medical Equipment Co., Ltd. (collectively referred to as “Sonmol”), a pharmaceutical and leading Chinese digital respiratory therapeutics company that provides consumer electric devices and connected devices for asthma control, and develops digital therapies and services platforms targeting chronic respiratory illnesses and other diseases. Kali Care During 2017, we invested $5 million to acquire 20% of the equity interests in Kali Care, a technology company that provides digital monitoring systems for medical devices. During the fourth quarter of 2020, we recognized an other than temporary impairment of $3.0 million ($2.3 million after-tax) on our underlying assets in this investment as a result of a reassessment of the future value of the business and continued reduction in operating cash flows. Desotec GmbH During 2009, we invested €574 thousand to acquire 23% of the equity interests in Desotec GmbH, a leading manufacturer of special assembly machines for bulk processing for the pharmaceutical, beauty and home and food and beverages markets. Other investments During August 2019, we invested an aggregate amount of $3.5 million in two preferred equity investments in sustainability companies Loop and PureCycle Technologies (“PureCycle”) that were accounted for at cost less impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for identical or similar investments of the same issuer. During 2020, we invested an additional $1.4 million in these two equity investments and also received $333 thousand of equity in PureCycle in exchange for our resource dedication for technological partnership and support. In November 2020, we increased the value of the PureCycle investment by $3.1 million based on observable price changes. In March 2021, PureCycle was purchased by a special purpose acquisition company and was subsequently listed on Nasdaq under the ticker PCT. At that time, our investment in PureCycle was converted into shares of PCT resulting in less than a 1% ownership interest. This investment is now recorded at fair value based on observable market prices for identical assets and the change in fair value is recorded as a net investment gain or loss in the Condensed Consolidated Statements of Income. For the three and six months ended June 30, 2021, we recorded a net unrealized loss on our investment in PureCycle of $1.6 million and a net unrealized gain of $15.2 million, respectively. Subsequent to the quarter end, on July 7, 2021, we investe d approximately $5.9 million to acquire 10% of the equity interests in YAT, a multi-functional, science-driven online skincare solutions company. There were no indications of impairment noted in the six months ended June 30, 2021 related to these investments.

RESTRUCTURING INITIATIVES

RESTRUCTURING INITIATIVES	6 Months Ended
	Jun. 30, 2021
Restructuring and Related Activities [Abstract]
RESTRUCTURING INITIATIVES	RESTRUCTURING INITIATIVES In late 2017, we began a business transformation to drive profitable sales growth, increase operational excellence, enhance our approach to innovation and improve organizational effectiveness. The primary focus of the plan is the Beauty + Home segment; however, certain global general and administrative functions are also being addressed. For the three and six months ended June 30, 2021, we recognized $4.9 million and $8.5 million of restructuring costs related to this plan, respectively. For the three and six months ended June 30, 2020, we recognized $7.3 million and $12.2 million of restructuring costs related to this plan, respectively. Using current exchange rates, we estimate total implementation costs of approximately $125 million for these initiatives, including costs that have been recognized to date. The cumulative expense incurred as of June 30, 2021 was $121.5 million. We have also made total capital investments related to this plan of approximately $50 million, with no further significant capital investments expected. As of June 30, 2021 we have recorded the following activity associated with the business transformation: Beginning Reserve at 12/31/2020 Net Charges for the Six Months Ended 6/30/2021 Cash Paid Interest and Ending Reserve at 6/30/2021 Employee severance $ 7,956 $ 144 $ (3,616) $ (130) $ 4,354 Professional fees and other costs 2,533 8,404 (9,431) (26) 1,480 Totals $ 10,489 $ 8,548 $ (13,047) $ (156) $ 5,834

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	6 Months Ended
	Jun. 30, 2021
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	SUBSEQUENT EVENTS On July 22, 2021, we signed a share purchase agreement for the acquisition of a majority stake in Voluntis, representing 64.6% of the share capital of Voluntis (on a non-diluted basis), at a price of €8.70 per share. Refer to Note 17 - Acquisitions for further details on the acquisition. On July 7, 2021, we investe d approximately $5.9 million to acquire 10% of the equity interests in YAT, a multi-functional, science-driven online skincare solutions company.

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
BASIS OF PRESENTATION	BASIS OF PRESENTATION The accompanying unaudited Condensed Consolidated Financial Statements include the accounts of AptarGroup, Inc. and our subsidiaries. The terms “AptarGroup”, “Aptar”, “Company”, “we”, “us” or “our” as used herein refer to AptarGroup, Inc. and our subsidiaries. All significant intercompany accounts and transactions have been eliminated. Certain previously reported amounts have been reclassified to conform to the current period presentation. In the opinion of management, the unaudited Condensed Consolidated Financial Statements (the “Condensed Consolidated Financial Statements”) include all normal recurring adjustments necessary for a fair statement of consolidated financial position, results of operations, comprehensive income, changes in equity and cash flows for the interim periods presented. The accompanying Condensed Consolidated Financial Statements have been prepared by the Company, pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) have been condensed or omitted pursuant to such rules and regulations, although we believe that the disclosures made are adequate to make the information presented not misleading. Also, certain financial position data included herein was derived from the audited Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2020 but does not include all disclosures required by U.S. GAAP. Accordingly, these Condensed Consolidated Financial Statements and related notes should be read in conjunction with the audited Consolidated Financial Statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2020. The results of operations of any interim period are not necessarily indicative of the results that may be expected for the year. Beginning July 1, 2018, we have applied highly inflationary accounting for our Argentinian subsidiary pursuant to U.S. GAAP. We have changed the functional currency from the Argentinian peso to the U.S. dollar. We remeasure our peso denominated assets and liabilities using the official rate. In September 2019, the President of Argentina reinstituted exchange controls restricting foreign currency purchases in an attempt to stabilize Argentina’s financial markets. As a result of these currency controls, a legal mechanism known as the Blue Chip Swap emerged in Argentina for reporting entities to transfer U.S. dollars. The Blue Chip Swap rate has diverged significantly from Argentina’s “official rate” due to the economic environment. During the second quarter of 2020, we transferred U.S. dollars into Argentina through the Blue Chip Swap method and we recognized a gain of $1.0 million. This gain helped to offset foreign currency losses due to our Argentinian peso exposure and devaluation against the U.S. dollar. Our Argentinian operations contributed less than 2.0% of consolidated net assets and revenues as of and for the six months ended June 30, 2021. There continues to be many uncertainties regarding the current COVID-19 pandemic, including the availability and adoption of approved vaccines within certain areas of the world and the potential for additional governmental actions that may be taken and/or extended in response to any further resurgence of the virus. However, in contrast to the preceding year, we are currently seeing a limited impact on our business related directly to the COVID-19 pandemic as economic activity and customer and product mix are approaching pre-pandemic levels. No impairments were recorded as of June 30, 2021 related to the COVID-19 pandemic. Due to uncertainty surrounding the situation, future results could be negatively affected by the pandemic and therefore our results could be materially impacted.
ADOPTION OF RECENT ACCOUNTING STANDARDS	ADOPTION OF RECENT ACCOUNTING STANDARDS Changes to U.S. GAAP are established by the Financial Accounting Standards Board (“FASB”) in the form of Accounting Standards Updates (“ASUs”) to the FASB’s Accounting Standards Codification. Effective January 1, 2021, we adopted ASU 2020-10, Codification Improvements, which updates various codification topics by clarifying or improving disclosure requirements to align with the SEC's regulations, and no material impacts were noted. Effective January 1, 2020, we adopted ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, issued by the FASB in June 2016, as well as the clarifying amendments subsequently issued. We applied the guidance using a modified retrospective approach and accordingly recognized an amount of $1.4 million as the cumulative adjustment to opening retained earnings in the first quarter of 2020. This is based on management's best estimates of specific losses on individual exposures particularly on current trade receivables, as well as the time value of money and reasonable and supportable information that is available at the reporting date about past events, current conditions and forecasts of future economic conditions. On an ongoing basis, we will contemplate forward-looking economic conditions in recording lifetime expected credit losses for our financial assets measured at cost, such as our trade receivables and certain other assets. In January 2017, the FASB issued ASU 2017-04, which provides guidance to simplify how an entity is required to test goodwill for impairm ent by eliminating Step 2 from the goodwill impairment test. As a result, impairment charges are required for the amount by which a reporting unit’s carrying amount exceeds its fair value up to the amount of its allocated goodwill. We adopted the standard on January 1, 2020 and did not record any impairment charges. In August 2018, the FASB issued ASU 2018-13, which amends disclosure requirements for fair value measurements. The new standard modifies disclosure requirements including removing requirements to disclose the valuation process for Level 3 measurements and adding requirements to disclose the changes in unrealized gains and losses for the period included in other comprehensive income for recurring Level 3 fair value measurements and the range and weighted average of significant unobservable inputs used to develop Level 3 measurements. We adopted the standard on January 1, 2020 and no material impacts were noted. In August 2018, the FASB issued ASU 2018-14, which amends disclosure requirements for defined benefit pension and other postretirement plans. The amendments in this update remove disclosures that are no longer considered cost beneficial, clarify the specific requirements of disclosures, and add disclosure requirements identified as relevant. We adopted the standard during the fourth quarter of 2020 and appropriate disclosures are included in the notes to the financial statements to the extent applicable. The provisions of the new standard do not have any effect on our financial statements. In August 2018, the FASB issued ASU 2018-15 to help entities evaluate the accounting for fees paid by a customer in a cloud computing arrangement (hosting arrangement) by providing guidance for determining when the arrangement includes a software license. The amendments in this update align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). Accordingly, the amendments require an entity (customer) in a hosting arrangement that is a service contract to follow the guidance in Subtopic 350-40 to determine which implementation costs to capitalize as an asset related to the service contract and which costs to expense. The amendments also require the entity (customer) to expense the capitalized implementation costs of a hosting arrangement that is a service contract over the term of the hosting arrangement, which includes reasonably certain renewals. We adopted the standard on January 1, 2020 and no material impacts were noted. Other accounting standards that have been issued by the FASB or other standards-setting bodies did not have a material impact on our Condensed Consolidated Financial Statements.
INCOME TAXES	INCOME TAXES We compute taxes on income in accordance with the tax rules and regulations of the many taxing authorities where the income is earned. The income tax rates imposed by these taxing authorities may vary substantially. Taxable income may differ from pre-tax income for financial accounting purposes. To the extent that these differences create timing differences between the tax basis of an asset or liability and our reported amount in the financial statements, an appropriate provision for deferred income taxes is made. We maintain our assertion that the cash and distributable reserves at our non-U.S. affiliates are indefinitely reinvested. At June 30, 2021, under currently enacted laws, we do not have a balance of foreign earnings that will be subject to U.S. taxation. We will provide for the necessary withholding and local income taxes when management decides that an affiliate should make a distribution. These decisions are made taking into consideration the financial requirements of the non-U.S. affiliates and the global cash management goals of the Company. We provide a liability for the amount of unrecognized tax benefits from uncertain tax positions. This liability is provided whenever we determine that a tax benefit will not meet a more-likely-than-not threshold for recognition. We are subject to the examination of our returns and other tax matters by the U.S. Internal Revenue Service and other tax authorities and governmental bodies. We believe that an adequate provision for any adjustments that may result from tax examinations exists. However, the outcome of tax audits cannot be predicted with certainty. If any issues addressed in our tax audits are resolved in a manner inconsistent with our expectations, we could be required to adjust its provision for income taxes in the period such resolution occurs. The resolution of each of these audits is not expected to be material to our Condensed Consolidated Financial Statements.

REVENUE (Tables)

REVENUE (Tables)	6 Months Ended
	Jun. 30, 2021
Revenue from Contract with Customer [Abstract]
Schedule of revenue by segment by geographic area	Revenue by segment and geography for the three and six months ended June 30, 2021 and 2020 is as follows: For the Three Months Ended June 30, 2021 Segment Europe Domestic Latin Asia Total Pharma $ 212,220 $ 93,527 $ 5,294 $ 14,302 $ 325,343 Beauty + Home 192,371 103,679 38,882 25,314 360,246 Food + Beverage 32,402 71,974 11,885 9,182 125,443 Total $ 436,993 $ 269,180 $ 56,061 $ 48,798 $ 811,032 For the Three Months Ended June 30, 2020 Segment Europe Domestic Latin Asia Total Pharma $ 201,813 $ 81,098 $ 6,987 $ 11,361 $ 301,259 Beauty + Home 152,412 94,349 29,893 23,132 299,786 Food + Beverage 27,841 54,478 6,489 9,452 98,260 Total $ 382,066 $ 229,925 $ 43,369 $ 43,945 $ 699,305 For the Six Months Ended June 30, 2021 Segment Europe Domestic Latin Asia Total Pharma $ 420,167 $ 182,822 $ 10,664 $ 25,522 $ 639,175 Beauty + Home 381,611 202,486 73,224 49,871 707,192 Food + Beverage 60,904 139,037 21,138 20,340 241,419 Total $ 862,682 $ 524,345 $ 105,026 $ 95,733 $ 1,587,786 For the Six Months Ended June 30, 2020 Segment Europe Domestic Latin Asia Total Pharma $ 391,943 $ 172,063 $ 13,566 $ 20,883 $ 598,455 Beauty + Home 339,362 176,194 66,074 42,716 624,346 Food + Beverage 56,610 112,068 14,523 14,856 198,057 Total $ 787,915 $ 460,325 $ 94,163 $ 78,455 $ 1,420,858
Schedule of opening and closing balances of contract assets and contract liabilities	The opening and closing balances of our contract asset and contract liabilities are as follows: Balance as of December 31, 2020 Balance as of June 30, 2021 Increase/ Contract asset (current) $ 16,109 $ 20,864 $ 4,755 Contract liability (current) 87,188 101,299 14,111 Contract liability (long-term) 21,584 23,129 1,545

INVENTORIES (Tables)

INVENTORIES (Tables)	6 Months Ended
	Jun. 30, 2021
Inventory Disclosure [Abstract]
Schedule of inventories, by component	Inventories, by component net of reserves, consisted of: June 30, December 31, Raw materials $ 134,582 $ 116,029 Work in process 135,695 115,870 Finished goods 159,163 147,480 Total $ 429,440 $ 379,379

GOODWILL AND OTHER INTANGIBLE_2

GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)	6 Months Ended
	Jun. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of changes in the carrying amount of goodwill	The changes in the carrying amount of goodwill by reporting segment since December 31, 2020 are as follows: Pharma Beauty + Food + Corporate Total Goodwill $ 436,731 $ 333,111 $ 128,679 $ 1,615 $ 900,136 Accumulated impairment losses — — — (1,615) (1,615) Balance as of December 31, 2020 $ 436,731 $ 333,111 $ 128,679 $ — $ 898,521 Foreign currency exchange effects (7,427) (3,167) (186) — (10,780) Goodwill $ 429,304 $ 329,944 $ 128,493 $ 1,615 $ 889,356 Accumulated impairment losses — — — (1,615) (1,615) Balance as of June 30, 2021 $ 429,304 $ 329,944 $ 128,493 $ — $ 887,741
Summary of amortized intangible assets	The table below shows a summary of intangible assets as of June 30, 2021 and December 31, 2020. June 30, 2021 December 31, 2020 Weighted Average Amortization Period (Years) Gross Accumulated Net Gross Accumulated Net Amortized intangible assets: Patents 13.8 $ 2,822 $ (1,465) $ 1,357 $ 2,861 $ (1,477) $ 1,384 Acquired technology 12.2 110,171 (41,264) 68,907 111,854 (36,943) 74,911 Customer relationships 13.5 284,613 (67,039) 217,574 286,644 (56,714) 229,930 Trademarks and trade names 6.8 45,653 (20,286) 25,367 46,174 (17,437) 28,737 License agreements and other 38.3 15,220 (6,410) 8,810 19,208 (9,861) 9,347 Total intangible assets 13.4 $ 458,479 $ (136,464) $ 322,015 $ 466,741 $ (122,432) $ 344,309
Schedule of future estimated amortization expense	Future estimated amortization expense for the years ending December 31 is as follows: 2021 $ 19,989 (remaining estimated amortization for 2021) 2022 38,319 2023 38,236 2024 35,097 2025 and thereafter 190,374

DEBT (Tables)

DEBT (Tables)	6 Months Ended
	Jun. 30, 2021
Debt Disclosure [Abstract]
Schedule of short-term debt	At June 30, 2021 and December 31, 2020, our notes payable, revolving credit facility and overdrafts consisted of the following: June 30, December 31, Notes payable 0.0% $ — $ 200 Revolving credit facility 1.45% — 52,000 Overdrafts 4.15% to 6.70% 2,965 — $ 2,965 $ 52,200
Schedule of long-term obligations	At June 30, 2021 and December 31, 2020, our long-term obligations consisted of the following: June 30, 2021 December 31, 2020 Notes payable 0.00% – 10.91%, due in monthly and annual installments through 2028 $ 17,754 $ 14,002 Senior unsecured notes 3.2%, due in 2022 75,000 75,000 Senior unsecured debts 1.4% USD floating swapped to 1.36% EUR fixed, equal annual installments through 2022 112,000 112,000 Senior unsecured notes 3.5%, due in 2023 125,000 125,000 Senior unsecured notes 1.0%, due in 2023 118,590 122,100 Senior unsecured notes 3.4%, due in 2024 50,000 50,000 Senior unsecured notes 3.5%, due in 2024 100,000 100,000 Senior unsecured notes 1.2%, due in 2024 237,180 244,200 Senior unsecured notes 3.6%, due in 2025 125,000 125,000 Senior unsecured notes 3.6%, due in 2026 125,000 125,000 Finance Lease Liabilities 32,021 30,025 Unamortized debt issuance costs (1,374) (1,663) $ 1,116,171 $ 1,120,664 Current maturities of long-term obligations (67,243) (65,666) Total long-term obligations $ 1,048,928 $ 1,054,998
Schedule of maturities of long-term debt	The aggregate long-term maturities, excluding finance lease liabilities, which are disclosed in Note 7, due annually from the current balance sheet date for the next five years are: Year One $ 63,069 Year Two 136,740 Year Three 347,690 Year Four 287,609 Year Five 250,262 Thereafter 154
Schedule of covenants on revolving credit facility and corporate long-term obligations	Our revolving credit facility and corporate long-term obligations require us to satisfy certain financial and other covenants including: Requirement Level at June 30, 2021 Consolidated Leverage Ratio (1) Maximum of 3.50 to 1.00 1.49 to 1.00 Consolidated Interest Coverage Ratio (1) Minimum of 3.00 to 1.00 18.93 to 1.00 ________________________________________

LEASES (Tables)

LEASES (Tables)	6 Months Ended
	Jun. 30, 2021
Leases [Abstract]
Schedule of components of lease expense	The components of lease expense for the three and six months ended June 30, 2021 and 2020 were as follows: Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Operating lease cost $ 6,044 $ 5,841 $ 11,833 $ 11,095 Finance lease cost: Amortization of right-of-use assets $ 1,099 $ 906 $ 2,075 $ 2,105 Interest on lease liabilities 375 369 687 717 Total finance lease cost $ 1,474 $ 1,275 $ 2,762 $ 2,822 Short-term lease and variable lease costs $ 2,444 $ 2,430 $ 5,572 $ 4,878
Schedule of supplemental cash flow information related to leases	Supplemental cash flow information related to leases was as follows: Six Months Ended June 30, 2021 2020 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 11,771 $ 11,662 Operating cash flows from finance leases 716 704 Financing cash flows from finance leases 2,337 2,545 Right-of-use assets obtained in exchange for lease obligations: Operating leases $ 4,739 $ 11,371 Finance leases 4,792 3,127

RETIREMENT AND DEFERRED COMPE_2

RETIREMENT AND DEFERRED COMPENSATION PLANS (Tables)	6 Months Ended
	Jun. 30, 2021
Retirement Benefits [Abstract]
Components of net periodic benefit cost	Components of Net Periodic Benefit Cost: Domestic Plans Foreign Plans Three Months Ended June 30, 2021 2020 2021 2020 Service cost $ 3,941 $ 3,562 $ 2,071 $ 1,767 Interest cost 1,604 1,536 208 340 Expected return on plan assets (3,064) (2,702) (721) (631) Amortization of net loss 2,501 1,294 591 514 Amortization of prior service cost — — 44 95 Net periodic benefit cost $ 4,982 $ 3,690 $ 2,193 $ 2,085 Domestic Plans Foreign Plans Six Months Ended June 30, 2021 2020 2021 2020 Service cost $ 8,168 $ 7,139 $ 4,149 $ 3,535 Interest cost 3,215 3,523 426 680 Expected return on plan assets (6,137) (6,124) (1,444) (1,265) Amortization of net loss 5,004 2,842 1,180 1,028 Amortization of prior service cost — — 89 192 Net periodic benefit cost $ 10,250 $ 7,380 $ 4,400 $ 4,170

ACCUMULATED OTHER COMPREHENSI_2

ACCUMULATED OTHER COMPREHENSIVE INCOME (Tables)	6 Months Ended
	Jun. 30, 2021
Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]
Changes in Accumulated Other Comprehensive Income/(Loss) by Component	Changes in Accumulated Other Comprehensive (Loss) Income by Component: Foreign Currency Defined Benefit Pension Plans Derivatives Total Balance - December 31, 2019 $ (257,124) $ (83,147) $ (1,677) $ (341,948) Other comprehensive (loss) income before reclassifications (23,134) — 1,758 (21,376) Amounts reclassified from accumulated other comprehensive income (loss) — 3,076 (1,008) 2,068 Net current-period other comprehensive (loss) income (23,134) 3,076 750 (19,308) Balance - June 30, 2020 $ (280,258) $ (80,071) $ (927) $ (361,256) Balance - December 31, 2020 $ (178,025) $ (102,322) $ (1,362) $ (281,709) Other comprehensive (loss) income before reclassifications (27,373) 442 4,066 (22,865) Amounts reclassified from accumulated other comprehensive income (loss) — 4,773 (3,257) 1,516 Net current-period other comprehensive (loss) income (27,373) 5,215 809 (21,349) Balance - June 30, 2021 $ (205,398) $ (97,107) $ (553) $ (303,058)
Reclassifications Out of Accumulated Other Comprehensive (Loss) Income	Reclassifications Out of Accumulated Other Comprehensive (Loss) Income: Details about Accumulated Other Amount Reclassified from Accumulated Other Comprehensive Income Affected Line in the Statement Three Months Ended June 30, 2021 2020 Defined Benefit Pension Plans Amortization of net loss $ 3,092 $ 1,808 (1) Amortization of prior service cost 44 95 (1) 3,136 1,903 Total before tax (750) (463) Tax impact $ 2,386 $ 1,440 Net of tax Derivatives Changes in cross currency swap: interest component $ (6) $ (525) Interest Expense Changes in cross currency swap: foreign exchange component 1,290 3,060 Miscellaneous, net $ 1,284 $ 2,535 Net of tax Total reclassifications for the period $ 3,670 $ 3,975 Details about Accumulated Other Amount Reclassified from Accumulated Other Comprehensive Income Affected Line in the Statement Six Months Ended June 30, 2021 2020 Defined Benefit Pension Plans Amortization of net loss $ 6,184 $ 3,870 (1) Amortization of prior service cost 89 192 (1) 6,273 4,062 Total before tax (1,500) (986) Tax impact $ 4,773 $ 3,076 Net of tax Derivatives Changes in cross currency swap: interest component $ (18) $ (1,288) Interest Expense Changes in cross currency swap: foreign exchange component (3,239) 280 Miscellaneous, net $ (3,257) $ (1,008) Net of tax Total reclassifications for the period $ 1,516 $ 2,068 ______________________________________________ (1) These accumulated other comprehensive income components are included in the computation of net periodic benefit costs, net of tax. See Note 8 – Retirement and Deferred Compensation Plans for additional details.

DERIVATIVE INSTRUMENTS AND HE_2

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES (Tables)	6 Months Ended
	Jun. 30, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Fair Value of Derivative Instruments in the Consolidated Balance Sheets	Fair Value of Derivative Instruments in the Condensed Consolidated Balance Sheets as of June 30, 2021 and December 31, 2020 June 30, 2021 December 31, 2020 Balance Sheet Location Derivatives Designated as Hedging Instruments Derivatives not Designated as Hedging Instruments Derivatives Designated as Hedging Instruments Derivatives not Designated as Hedging Instruments Derivative Assets Foreign Exchange Contracts Prepaid and other $ — $ 30 $ — $ 322 $ — $ 30 $ — $ 322 Derivative Liabilities Foreign Exchange Contracts Accounts payable, accrued and other liabilities $ — $ 1,526 $ — $ 146 Cross Currency Swap Contract (1) Accounts payable, accrued and other liabilities 4,056 — 8,309 — $ 4,056 $ 1,526 $ 8,309 $ 146 __________________________ (1) This cross currency swap contract is composed of both an interest component and a foreign exchange component.
Schedule of Effect of Cash Flow Hedge Accounting on Accumulated Other Comprehensive Income (Loss)	The Effect of Cash Flow Hedge Accounting on Accumulated Other Comprehensive Income (Loss) for the Three Months Ended June 30, 2021 and 2020 Derivatives in Cash Flow Hedging Amount of Gain (Loss) Location of (Loss) Amount of Gain (Loss) Total Amount of Affected Income Statement Line Item 2021 2020 2021 2020 Cross currency swap contract: Interest component $ 295 $ (208) Interest expense $ 6 $ 525 $ (7,175) Foreign exchange component (1,290) (3,060) Miscellaneous, net (1,290) (3,060) (2,028) $ (995) $ (3,268) $ (1,284) $ (2,535) The Effect of Cash Flow Hedge Accounting on Accumulated Other Comprehensive Income (Loss) for the Six Months Ended June 30, 2021 and 2020 Derivatives in Cash Flow Hedging Amount of Gain (Loss) Location of (Loss) Amount of Gain (Loss) Total Amount of Affected Income Statement Line Item 2021 2020 2021 2020 Cross currency swap contract: Interest component $ 827 $ 2,038 Interest expense $ 18 $ 1,288 $ (14,590) Foreign exchange component 3,239 (280) Miscellaneous, net 3,239 (280) (2,991) $ 4,066 $ 1,758 $ 3,257 $ 1,008
Schedule of Effect of Derivatives Not Designated as Hedging Instruments on the Consolidated Statements of Income	The Effect of Derivatives Not Designated as Hedging Instruments on the Condensed Consolidated Statements of Income for the Three Months Ended June 30, 2021 and 2020 Derivatives Not Designated Location of (Loss) Gain Recognized Amount of (Loss) Gain 2021 2020 Foreign Exchange Contracts Other (Expense) Income: $ (1,176) $ (940) $ (1,176) $ (940) The Effect of Derivatives Not Designated as Hedging Instruments on the Condensed Consolidated Statements of Income for the Six Months Ended June 30, 2021 and 2020 Derivatives Not Designated Location of (Loss) Gain Recognized Amount of (Loss) Gain 2021 2020 Foreign Exchange Contracts Other (Expense) Income: $ (1,689) $ 807 $ (1,689) $ 807
Schedule of offsetting derivative assets and liabilities	Gross Amounts Offset in the Statement of Financial Position Net Amounts Presented in the Statement of Financial Position Gross Amounts not Offset in the Statement of Financial Position Gross Amount Financial Instruments Cash Collateral Received Net Amount Description June 30, 2021 Derivative Assets $ 30 — $ 30 — — $ 30 Total Assets $ 30 — $ 30 — — $ 30 Derivative Liabilities $ 5,582 — $ 5,582 — — $ 5,582 Total Liabilities $ 5,582 — $ 5,582 — — $ 5,582 December 31, 2020 Derivative Assets $ 322 — $ 322 — — $ 322 Total Assets $ 322 — $ 322 — — $ 322 Derivative Liabilities $ 8,455 — $ 8,455 — — $ 8,455 Total Liabilities $ 8,455 — $ 8,455 — — $ 8,455

FAIR VALUE (Tables)

FAIR VALUE (Tables)	6 Months Ended
	Jun. 30, 2021
Fair Value Disclosures [Abstract]
Schedule of fair values of financial assets and liabilities	As of June 30, 2021, the fair values of our financial assets and liabilities were categorized as follows: Total Level 1 Level 2 Level 3 Assets Investment in equity securities (1) $ 20,595 $ 20,595 $ — $ — Foreign exchange contracts (2) 30 — 30 — Total assets at fair value $ 20,625 $ 20,595 $ 30 $ — Liabilities Foreign exchange contracts (2) $ 1,526 $ — $ 1,526 $ — Cross currency swap contract (2) 4,056 — 4,056 — Contingent consideration obligation 33,090 — — 33,090 Total liabilities at fair value $ 38,672 $ — $ 5,582 $ 33,090 As of December 31, 2020, the fair values of our financial assets and liabilities were categorized as follows: Total Level 1 Level 2 Level 3 Assets Foreign exchange contracts (2) $ 322 $ — $ 322 $ — Total assets at fair value $ 322 $ — $ 322 $ — Liabilities Foreign exchange contracts (2) $ 146 $ — $ 146 $ — Cross currency swap contract (2) 8,309 — 8,309 — Contingent consideration obligation 31,140 — — 31,140 Total liabilities at fair value $ 39,595 $ — $ 8,455 $ 31,140 ________________________________________________ (1) Investment in PureCycle Technologies (PCT). See Note 18 - Investment in Equity Securities for discussion of this investment. (2) Market approach valuation technique based on observable market transactions of spot and forward rates.
Schedule of contingent consideration arrangements, fair value	We consider these obligations Level 3 liabilities and have estimated the aggregate fair value for these contingent consideration arrangements as follows: June 30, 2021 December 31, 2020 Fusion Acquisition $ 28,010 $ 26,910 Noble Acquisition 5,080 4,230 $ 33,090 $ 31,140
Summary of changes in Level 3 fair value measurements	The following table provides a summary of changes in our Level 3 fair value measurements: Balance, December 31, 2020 $ 31,140 Increase in fair value recorded in earnings 1,950 Balance, June 30, 2021 $ 33,090

STOCK-BASED COMPENSATION (Table

STOCK-BASED COMPENSATION (Tables)	6 Months Ended
	Jun. 30, 2021
Share-based Payment Arrangement [Abstract]
Weighted-average assumptions used to estimate fair value of restricted stock units	Inputs and assumptions used to calculate the fair value are shown in the table below. The fair value of these RSUs is expensed over the vesting period using the straight-line method or using the graded vesting method when an employee becomes eligible to retain the award at retirement. Six Months Ended June 30, 2021 2020 Fair value per stock award $ 171.63 $ 94.98 Grant date stock price $ 141.59 $ 83.93 Assumptions: Aptar's stock price expected volatility 21.40 % 23.80 % Expected average volatility of peer companies 50.00 % 48.50 % Correlation assumption 58.10 % 63.50 % Risk-free interest rate 0.32 % 0.31 % Dividend yield assumption 1.02 % 1.72 %
Summary of restricted stock unit activity	A summary of RSU activity as of June 30, 2021 and changes during the six month period then ended is presented below: Time-Based RSUs Performance-Based RSUs Units Weighted Average Units Weighted Average Nonvested at January 1, 2021 576,198 $ 92.47 590,064 $ 100.27 Granted 140,316 139.25 169,974 152.51 Vested (134,808) 91.39 (71,994) 128.70 Forfeited (3,244) 99.42 (31,872) 91.67 Nonvested at June 30, 2021 578,462 $ 107.45 656,172 $ 111.10
Schedule of compensation expense, fair value, and intrinsic value related to RSU's	Six Months Ended June 30, 2021 2020 Compensation expense $ 21,579 $ 16,353 Fair value of units vested 20,778 10,696 Intrinsic value of units vested 28,259 12,821
Summary of option activity	A summary of option activity under our stock plans during the six months ended June 30, 2021 is presented below: Stock Awards Plans Director Stock Option Plans Options Weighted Average Options Weighted Average Outstanding, January 1, 2021 3,998,047 $ 70.28 99,200 $ 60.80 Granted — — — — Exercised (816,058) 64.74 (47,500) 57.40 Forfeited or expired (10,153) 75.46 — — Outstanding at June 30, 2021 3,171,836 $ 71.69 51,700 $ 63.91 Exercisable at June 30, 2021 3,171,836 $ 71.69 51,700 $ 63.91 Weighted-Average Remaining Contractual Term (Years): Outstanding at June 30, 2021 4.5 2.6 Exercisable at June 30, 2021 4.5 2.6 Aggregate Intrinsic Value: Outstanding at June 30, 2021 $ 221,908 $ 4,019 Exercisable at June 30, 2021 $ 221,908 $ 4,019 Intrinsic Value of Options Exercised During the Six Months Ended: June 30, 2021 $ 63,407 $ 4,248 June 30, 2020 $ 26,027 $ 1,973
Schedule of compensation expense, and fair value related to options	Six Months Ended June 30, 2021 2020 Compensation expense (included in SG&A) $ 185 $ 1,051 Compensation expense (included in Cost of sales) 42 200 Compensation expense, Total $ 227 $ 1,251 Compensation expense, net of tax 174 951 Grant date fair value of options vested 2,421 7,565

EARNINGS PER SHARE (Tables)

EARNINGS PER SHARE (Tables)	6 Months Ended
	Jun. 30, 2021
Earnings Per Share [Abstract]
Reconciliation of Basic and Diluted Earnings Per Share	The reconciliation of basic and diluted earnings per share for the three and six months ended June 30, 2021 and 2020 is as follows: Three Months Ended June 30, 2021 June 30, 2020 Diluted Basic Diluted Basic Consolidated operations Income available to common stockholders $ 55,276 $ 55,276 $ 41,839 $ 41,839 Average equivalent shares Shares of common stock 65,818 65,818 64,262 64,262 Effect of dilutive stock-based compensation Stock options 1,727 — 1,661 — Restricted stock 541 — 461 — Total average equivalent shares 68,086 65,818 66,384 64,262 Net income per share $ 0.81 $ 0.84 $ 0.63 $ 0.65 Six Months Ended June 30, 2021 June 30, 2020 Diluted Basic Diluted Basic Consolidated operations Income available to common stockholders $ 139,228 $ 139,228 $ 97,092 $ 97,092 Average equivalent shares Shares of common stock 65,525 65,525 64,135 64,135 Effect of dilutive stock-based compensation Stock options 1,804 — 1,734 — Restricted stock 540 — 377 — Total average equivalent shares 67,869 65,525 66,246 64,135 Net income per share $ 2.05 $ 2.12 $ 1.47 $ 1.51

SEGMENT INFORMATION (Tables)

SEGMENT INFORMATION (Tables)	6 Months Ended
	Jun. 30, 2021
Segment Reporting [Abstract]
Financial information regarding the Company's reportable segments	Financial information regarding our reporting segments is shown below: Three Months Ended Six Months Ended 2021 2020 2021 2020 Total Sales: Pharma $ 328,549 $ 303,885 $ 644,360 $ 603,475 Beauty + Home 366,641 306,469 720,018 636,935 Food + Beverage 125,918 99,023 242,621 199,324 Total Sales $ 821,108 $ 709,377 $ 1,606,999 $ 1,439,734 Less: Intersegment Sales: Pharma $ 3,206 $ 2,626 $ 5,185 $ 5,020 Beauty + Home 6,395 6,683 12,826 12,589 Food + Beverage 475 763 1,202 1,267 Total Intersegment Sales $ 10,076 $ 10,072 $ 19,213 $ 18,876 Net Sales: Pharma $ 325,343 $ 301,259 $ 639,175 $ 598,455 Beauty + Home 360,246 299,786 707,192 624,346 Food + Beverage 125,443 98,260 241,419 198,057 Net Sales $ 811,032 $ 699,305 $ 1,587,786 $ 1,420,858 Adjusted EBITDA (1): Pharma $ 105,979 $ 104,099 $ 214,463 $ 212,441 Beauty + Home 37,910 23,974 73,266 58,221 Food + Beverage 19,626 17,785 39,616 33,192 Corporate & Other, unallocated (15,959) (9,279) (27,566) (23,107) Acquisition-related costs (2) (2,434) (3,592) (2,434) (5,866) Restructuring Initiatives (3) (4,876) (7,331) (8,548) (12,170) Net investment (loss) gain (4) (1,611) — 15,198 — Depreciation and amortization (57,790) (56,429) (115,228) (107,235) Interest Expense (7,175) (8,734) (14,590) (17,122) Interest Income 624 175 1,005 350 Income before Income Taxes $ 74,294 $ 60,668 $ 175,182 $ 138,704 ________________________________________________ (1) We evaluate performance of our reporting segments and allocate resources based upon Adjusted EBITDA. Adjusted EBITDA is defined as earnings before net interest, taxes, depreciation, amortization, unallocated corporate expenses, restructuring initiatives, acquisition-related costs, net investment gains and losses related to observable market price changes on equity securities and other special items. (2) Acquisition-related costs include transaction costs and purchase accounting adjustments related to acquisitions and investments (see Note 17 – Acquisitions and Note 18 – Investment in Equity Securities for further details). (3) Restructuring Initiatives includes expense items for the three and six months ended June 30, 2021 and 2020 as follows (see Note 19 – Restructuring Initiatives for further details): Three Months Ended Six Months Ended 2021 2020 2021 2020 Restructuring Initiatives by Segment Pharma $ 38 $ (111) $ 73 $ (142) Beauty + Home 1,457 7,324 2,553 12,231 Food + Beverage 117 75 38 178 Corporate & Other 3,264 43 5,884 (97) Total Restructuring Initiatives $ 4,876 $ 7,331 $ 8,548 $ 12,170 (4) Net investment (loss) gain represents the change in fair value of our investment in PCT (see Note 18 – Investment in Equity Securities for further details).
Restructuring Initiatives	Restructuring Initiatives includes expense items for the three and six months ended June 30, 2021 and 2020 as follows (see Note 19 – Restructuring Initiatives for further details): Three Months Ended Six Months Ended 2021 2020 2021 2020 Restructuring Initiatives by Segment Pharma $ 38 $ (111) $ 73 $ (142) Beauty + Home 1,457 7,324 2,553 12,231 Food + Beverage 117 75 38 178 Corporate & Other 3,264 43 5,884 (97) Total Restructuring Initiatives $ 4,876 $ 7,331 $ 8,548 $ 12,170

ACQUISITIONS (Tables)

ACQUISITIONS (Tables)	6 Months Ended
	Jun. 30, 2021
Business Combinations [Abstract]
Summary of assets acquired and liabilities assumed at estimated fair value	The following table summarizes the assets acquired and liabilities assumed in the Fusion Acquisition as of the acquisition date at estimated fair value. 2020 Assets Cash and equivalents $ 1,010 Accounts receivable 4,380 Inventories 386 Prepaid and other 1,090 Property, plant and equipment 2,885 Goodwill 103,130 Intangible assets 79,900 Operating lease right-of-use assets 4,744 Other miscellaneous assets 65 Liabilities Accounts payable, accrued and other liabilities 5,641 Deferred income taxes — Operating lease liabilities 4,207 Deferred and other non-current liabilities 322 Net assets acquired $ 187,420
Summary of the fair value estimates of the acquired identifiable intangible assets and weighted-average useful lives as of the acquisition date	The following table is a summary of the fair value estimates of the acquired identifiable intangible assets and weighted-average useful lives as of the acquisition date: 2020 Weighted-Average Useful Life (in Years) Estimated Fair Value of Assets Acquired technology 4 $ 4,600 Customer relationships 13 62,300 Trademarks and trade names 4 10,300 License agreements and other 0.25 2,700 Total $ 79,900

INVESTMENT IN EQUITY SECURITI_2

INVESTMENT IN EQUITY SECURITIES (Tables)	6 Months Ended
	Jun. 30, 2021
Equity Method Investments and Joint Ventures [Abstract]
Schedule of investments in equity securities	Our investment in equity securities consisted of the following: June 30, December 31, Equity Method Investments: BTY $ 33,005 $ 33,020 Sonmol 5,710 5,598 Kali Care 422 535 Desotec GmbH 943 964 Other Investments: PureCycle 20,595 5,397 Loop 2,894 2,894 Others 1,631 1,679 $ 65,200 $ 50,087

RESTRUCTURING INITIATIVES (Tabl

RESTRUCTURING INITIATIVES (Tables)	6 Months Ended
	Jun. 30, 2021
Restructuring and Related Activities [Abstract]
Schedule of Restructuring Reserve by Type of Cost	As of June 30, 2021 we have recorded the following activity associated with the business transformation: Beginning Reserve at 12/31/2020 Net Charges for the Six Months Ended 6/30/2021 Cash Paid Interest and Ending Reserve at 6/30/2021 Employee severance $ 7,956 $ 144 $ (3,616) $ (130) $ 4,354 Professional fees and other costs 2,533 8,404 (9,431) (26) 1,480 Totals $ 10,489 $ 8,548 $ (13,047) $ (156) $ 5,834

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - (Details) - USD ($)	3 Months Ended	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Mar. 31, 2020	Dec. 31, 2019
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Impairment charges		$ 0
Adoption of CECL standard	$ 1,645,986,000	$ 1,986,663,000	$ 1,900,795,000	$ 1,850,785,000	$ 1,587,623,000	$ 1,572,252,000
Argentina
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Foreign currency, gain recognized	1,000,000
Maximum | Argentina | Revenue Benchmark | Geographic concentration risk
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Concentration risk percentage (less than)		2.00%
Retained Earnings
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Adoption of CECL standard	$ 1,573,392,000	$ 1,734,638,000	$ 1,704,336,000	$ 1,643,825,000	$ 1,554,665,000	1,523,820,000
Cumulative Effect, Period of Adoption, Adjustment
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Adoption of CECL standard						(1,377,000)
Cumulative Effect, Period of Adoption, Adjustment | Retained Earnings
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Adoption of CECL standard						(1,377,000)
Accounting Standards Update 2016-13 | Cumulative Effect, Period of Adoption, Adjustment | Retained Earnings
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Adoption of CECL standard						$ (1,400,000)

REVENUE - Revenue by Geographic

REVENUE - Revenue by Geographic Segment (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
REVENUE
Net revenue	$ 811,032	$ 699,305	$ 1,587,786	$ 1,420,858
Pharma
REVENUE
Net revenue	325,343	301,259	639,175	598,455
Beauty + Home
REVENUE
Net revenue	360,246	299,786	707,192	624,346
Food + Beverage
REVENUE
Net revenue	125,443	98,260	241,419	198,057
Europe
REVENUE
Net revenue	436,993	382,066	862,682	787,915
Europe | Pharma
REVENUE
Net revenue	212,220	201,813	420,167	391,943
Europe | Beauty + Home
REVENUE
Net revenue	192,371	152,412	381,611	339,362
Europe | Food + Beverage
REVENUE
Net revenue	32,402	27,841	60,904	56,610
Domestic
REVENUE
Net revenue	269,180	229,925	524,345	460,325
Domestic | Pharma
REVENUE
Net revenue	93,527	81,098	182,822	172,063
Domestic | Beauty + Home
REVENUE
Net revenue	103,679	94,349	202,486	176,194
Domestic | Food + Beverage
REVENUE
Net revenue	71,974	54,478	139,037	112,068
Latin America
REVENUE
Net revenue	56,061	43,369	105,026	94,163
Latin America | Pharma
REVENUE
Net revenue	5,294	6,987	10,664	13,566
Latin America | Beauty + Home
REVENUE
Net revenue	38,882	29,893	73,224	66,074
Latin America | Food + Beverage
REVENUE
Net revenue	11,885	6,489	21,138	14,523
Asia
REVENUE
Net revenue	48,798	43,945	95,733	78,455
Asia | Pharma
REVENUE
Net revenue	14,302	11,361	25,522	20,883
Asia | Beauty + Home
REVENUE
Net revenue	25,314	23,132	49,871	42,716
Asia | Food + Beverage
REVENUE
Net revenue	$ 9,182	$ 9,452	$ 20,340	$ 14,856

REVENUE - Contract Assets and C

REVENUE - Contract Assets and Contract Liabilities (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Revenue from Contract with Customer [Abstract]
Contract asset (current)	$ 20,864	$ 16,109
Increase / (decrease) in contract asset (current)	4,755
Contract liability (current)	101,299	87,188
Increase / (decrease) in contract liability (current)	14,111
Contract liability (long-term)	23,129	$ 21,584
Increase / (decrease) in contract liability (long-term)	1,545
Revenue recognized previously included in current contract liabilities	49,900
Revenue recognized previously included in current contract liabilities at the beginning of the year	$ 29,800

INVENTORIES (Details)

INVENTORIES (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Inventories, by component
Raw materials	$ 134,582	$ 116,029
Work in process	135,695	115,870
Finished goods	159,163	147,480
Total	$ 429,440	$ 379,379

GOODWILL AND OTHER INTANGIBLE_3

GOODWILL AND OTHER INTANGIBLE ASSETS - Schedule of Goodwill (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Changes in the carrying amount of goodwill
Goodwill, Gross	$ 889,356	$ 900,136
Accumulated impairment losses	(1,615)	(1,615)
Goodwill, beginning balance	898,521
Foreign currency exchange effects	(10,780)
Goodwill, ending balance	887,741
Operating segment | Pharma
Changes in the carrying amount of goodwill
Goodwill, Gross	429,304	436,731
Accumulated impairment losses	0	0
Goodwill, beginning balance	436,731
Foreign currency exchange effects	(7,427)
Goodwill, ending balance	429,304
Operating segment | Beauty + Home
Changes in the carrying amount of goodwill
Goodwill, Gross	329,944	333,111
Accumulated impairment losses	0	0
Goodwill, beginning balance	333,111
Foreign currency exchange effects	(3,167)
Goodwill, ending balance	329,944
Operating segment | Food + Beverage
Changes in the carrying amount of goodwill
Goodwill, Gross	128,493	128,679
Accumulated impairment losses	0	0
Goodwill, beginning balance	128,679
Foreign currency exchange effects	(186)
Goodwill, ending balance	128,493
Corporate Non-Segment
Changes in the carrying amount of goodwill
Goodwill, Gross	1,615	1,615
Accumulated impairment losses	(1,615)	$ (1,615)
Goodwill, beginning balance	0
Foreign currency exchange effects	0
Goodwill, ending balance	$ 0

GOODWILL AND OTHER INTANGIBLE_4

GOODWILL AND OTHER INTANGIBLE ASSETS - Summary of Intangible Assets (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Amortized intangible assets
Gross Carrying Amount	$ 458,479		$ 458,479		$ 466,741
Accumulated Amortization	(136,464)		(136,464)		(122,432)
Net Value	322,015		322,015		344,309
Aggregate amortization expense	9,811	$ 12,320	$ 19,622	$ 20,334
Weighted Average
Amortized intangible assets
Amortization Period (in years)			13 years 4 months 24 days
Patents
Amortized intangible assets
Gross Carrying Amount	2,822		$ 2,822		2,861
Accumulated Amortization	(1,465)		(1,465)		(1,477)
Net Value	1,357		$ 1,357		1,384
Patents | Weighted Average
Amortized intangible assets
Amortization Period (in years)			13 years 9 months 18 days
Acquired technology
Amortized intangible assets
Gross Carrying Amount	110,171		$ 110,171		111,854
Accumulated Amortization	(41,264)		(41,264)		(36,943)
Net Value	68,907		$ 68,907		74,911
Acquired technology | Weighted Average
Amortized intangible assets
Amortization Period (in years)			12 years 2 months 12 days
Customer relationships
Amortized intangible assets
Gross Carrying Amount	284,613		$ 284,613		286,644
Accumulated Amortization	(67,039)		(67,039)		(56,714)
Net Value	217,574		$ 217,574		229,930
Customer relationships | Weighted Average
Amortized intangible assets
Amortization Period (in years)			13 years 6 months
Trademarks and trade names
Amortized intangible assets
Gross Carrying Amount	45,653		$ 45,653		46,174
Accumulated Amortization	(20,286)		(20,286)		(17,437)
Net Value	25,367		$ 25,367		28,737
Trademarks and trade names | Weighted Average
Amortized intangible assets
Amortization Period (in years)			6 years 9 months 18 days
License agreements and other
Amortized intangible assets
Gross Carrying Amount	15,220		$ 15,220		19,208
Accumulated Amortization	(6,410)		(6,410)		(9,861)
Net Value	$ 8,810		$ 8,810		$ 9,347
License agreements and other | Weighted Average
Amortized intangible assets
Amortization Period (in years)			38 years 3 months 18 days

GOODWILL AND OTHER INTANGIBLE_5

GOODWILL AND OTHER INTANGIBLE ASSETS - Future Amortization Expense (Details) $ in Thousands	Jun. 30, 2021USD ($)
Statement of Financial Position [Abstract]
2021	$ 19,989
2022	38,319
2023	38,236
2024	35,097
2025 and thereafter	$ 190,374

INCOME TAXES (Details)

INCOME TAXES (Details)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Income Tax Disclosure [Abstract]
Effective income tax rate (as a percent)	25.60%	31.00%	20.50%	30.00%

DEBT - Short-term Debt Obligati

DEBT - Short-term Debt Obligations (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Short-term Debt [Line Items]
Notes payable, revolving credit facility and overdrafts	$ 2,965	$ 52,200
Notes payable
Short-term Debt [Line Items]
Interest rate (as a percent)	0.00%
Notes payable, revolving credit facility and overdrafts	$ 0	200
Revolving credit facility
Short-term Debt [Line Items]
Interest rate (as a percent)	1.45%
Notes payable, revolving credit facility and overdrafts	$ 0	52,000
Overdrafts
Short-term Debt [Line Items]
Notes payable, revolving credit facility and overdrafts	$ 2,965	$ 0
Overdrafts | Minimum
Short-term Debt [Line Items]
Interest rate (as a percent)	4.15%
Overdrafts | Maximum
Short-term Debt [Line Items]
Interest rate (as a percent)	6.70%

DEBT - Narrative (Details)

DEBT - Narrative (Details)	Jun. 30, 2021USD ($)extension	Dec. 31, 2020USD ($)	Dec. 31, 2020EUR (€)	Oct. 31, 2020USD ($)
Line of Credit Facility [Line Items]
Short-term borrowing	$ 2,965,000	$ 52,200,000
Commercial Paper
Line of Credit Facility [Line Items]
Short-term borrowing, maximum borrowing capacity				$ 30,000,000
Short-term borrowing	$ 0	0
Revolving Credit Facility
Line of Credit Facility [Line Items]
Line of credit facility, number of extensions | extension	2
Line of credit facility, duration of extension (in years)	1 year
Line of credit facility, maximum borrowing capacity	$ 600,000,000
Line of credit facility, increase limit	300,000,000
Long-term line of credit	0
Compensating balance, amount	0
Prior Credit Facility
Line of Credit Facility [Line Items]
Long-term line of credit		52,000,000	€ 0
Senior unsecured debts 1.4% USD floating swapped to 1.36% EUR fixed, equal annual installments through 2022
Line of Credit Facility [Line Items]
Remaining outstanding under the amended term facility	$ 112,000,000	$ 112,000,000

DEBT - Long-Term Obligations (D

DEBT - Long-Term Obligations (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020	Dec. 31, 2017
Components of the company's debt obligations
Finance Lease Liabilities	$ 32,021	$ 30,025
Unamortized debt issuance costs	(1,374)	(1,663)
Long-term debt and lease obligation, including current maturities	1,116,171	1,120,664
Current maturities of long-term obligations	(67,243)	(65,666)
Total long-term obligations	$ 1,048,928	1,054,998
Consolidated Leverage Ratio	1.49
Consolidated Interest Coverage Ratio	18.93
Minimum
Components of the company's debt obligations
Consolidated Interest Coverage Ratio	3
Maximum
Components of the company's debt obligations
Consolidated Leverage Ratio	3.50
Notes payable 0.00% – 10.91%, due in monthly and annual installments through 2028
Components of the company's debt obligations
Long-term debt, gross	$ 17,754	14,002
Notes payable 0.00% – 10.91%, due in monthly and annual installments through 2028 | Minimum
Components of the company's debt obligations
Interest rate on notes (as a percent)	0.00%
Notes payable 0.00% – 10.91%, due in monthly and annual installments through 2028 | Maximum
Components of the company's debt obligations
Interest rate on notes (as a percent)	10.91%
Senior unsecured notes 3.2%, due in 2022
Components of the company's debt obligations
Long-term debt, gross	$ 75,000	75,000
Interest rate on notes (as a percent)	3.20%
Senior unsecured debts 1.4% USD floating swapped to 1.36% EUR fixed, equal annual installments through 2022
Components of the company's debt obligations
Long-term debt, gross	$ 112,000	112,000
Interest rate on notes (as a percent)	1.36%		1.36%
Floating interest rate prior to conversion to a fixed interest rate (as a percent)	1.40%
Senior unsecured notes 3.5%, due in 2023
Components of the company's debt obligations
Long-term debt, gross	$ 125,000	125,000
Interest rate on notes (as a percent)	3.50%
Senior unsecured notes 1.0%, due in 2023
Components of the company's debt obligations
Long-term debt, gross	$ 118,590	122,100
Interest rate on notes (as a percent)	1.00%
Senior unsecured notes 3.4%, due in 2024
Components of the company's debt obligations
Long-term debt, gross	$ 50,000	50,000
Interest rate on notes (as a percent)	3.40%
Senior unsecured notes 3.5%, due in 2024
Components of the company's debt obligations
Long-term debt, gross	$ 100,000	100,000
Interest rate on notes (as a percent)	3.50%
Senior unsecured notes 1.2%, due in 2024
Components of the company's debt obligations
Long-term debt, gross	$ 237,180	244,200
Interest rate on notes (as a percent)	1.20%
Senior unsecured notes 3.6%, due in 2025
Components of the company's debt obligations
Long-term debt, gross	$ 125,000	125,000
Interest rate on notes (as a percent)	3.60%
Senior unsecured notes 3.6%, due in 2026
Components of the company's debt obligations
Long-term debt, gross	$ 125,000	$ 125,000
Interest rate on notes (as a percent)	3.60%

DEBT - Long-Term Maturities (De

DEBT - Long-Term Maturities (Details) $ in Thousands	Jun. 30, 2021USD ($)
Debt Disclosure [Abstract]
Year One	$ 63,069
Year Two	136,740
Year Three	347,690
Year Four	287,609
Year Five	250,262
Thereafter	$ 154

LEASES - Components of Lease Ex

LEASES - Components of Lease Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Components of lease expense:
Operating lease cost	$ 6,044	$ 5,841	$ 11,833	$ 11,095
Finance lease cost:
Amortization of right-of-use assets	1,099	906	2,075	2,105
Interest on lease liabilities	375	369	687	717
Total finance lease cost	1,474	1,275	2,762	2,822
Short-term lease and variable lease costs	$ 2,444	$ 2,430	$ 5,572	$ 4,878

LEASES - Supplemental Cash Flow

LEASES - Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$ 11,771	$ 11,662
Operating cash flows from finance leases	716	704
Financing cash flows from finance leases	2,337	2,545
Right-of-use assets obtained in exchange for lease obligations:
Operating leases	4,739	11,371
Finance leases	$ 4,792	$ 3,127

RETIREMENT AND DEFERRED COMPE_3

RETIREMENT AND DEFERRED COMPENSATION PLANS - Components of Net Periodic Benefit Cost (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
United States
Components of net periodic benefit cost:
Service cost	$ 3,941	$ 3,562	$ 8,168	$ 7,139
Interest cost	1,604	1,536	3,215	3,523
Expected return on plan assets	(3,064)	(2,702)	(6,137)	(6,124)
Amortization of net loss	2,501	1,294	5,004	2,842
Amortization of prior service cost	0	0	0	0
Net periodic benefit cost	4,982	3,690	10,250	7,380
Foreign Plans
Components of net periodic benefit cost:
Service cost	2,071	1,767	4,149	3,535
Interest cost	208	340	426	680
Expected return on plan assets	(721)	(631)	(1,444)	(1,265)
Amortization of net loss	591	514	1,180	1,028
Amortization of prior service cost	44	95	89	192
Net periodic benefit cost	$ 2,193	$ 2,085	$ 4,400	$ 4,170

RETIREMENT AND DEFERRED COMPE_4

RETIREMENT AND DEFERRED COMPENSATION PLANS - Narrative (Details)	6 Months Ended
	Jun. 30, 2021USD ($)
United States
Changes in the benefit obligations and plan assets
Minimum funding requirements	$ 0
Defined benefit plan, plan assets, contributions by employer	1,000,000
Foreign Plans
Changes in the benefit obligations and plan assets
Defined benefit plan, plan assets, contributions by employer	$ 2,300,000

ACCUMULATED OTHER COMPREHENSI_3

ACCUMULATED OTHER COMPREHENSIVE INCOME - Changes in Accumulated Other Comprehensive Income by Component (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Accumulated other comprehensive income activity
Balance at the beginning of the period	$ 1,850,389
Other comprehensive (loss) income before reclassifications	(22,865)	$ (21,376)
Amounts reclassified from accumulated other comprehensive income (loss)	1,516	2,068
Net current-period other comprehensive (loss) income	(21,349)	(19,308)
Balance at the end of the period	1,986,282
Accumulated Other Comprehensive Income/(Loss)
Accumulated other comprehensive income activity
Balance at the beginning of the period	(281,709)	(341,948)
Balance at the end of the period	(303,058)	(361,256)
Foreign Currency
Accumulated other comprehensive income activity
Balance at the beginning of the period	(178,025)	(257,124)
Other comprehensive (loss) income before reclassifications	(27,373)	(23,134)
Amounts reclassified from accumulated other comprehensive income (loss)	0	0
Net current-period other comprehensive (loss) income	(27,373)	(23,134)
Balance at the end of the period	(205,398)	(280,258)
Defined Benefit Pension Plans
Accumulated other comprehensive income activity
Balance at the beginning of the period	(102,322)	(83,147)
Other comprehensive (loss) income before reclassifications	442	0
Amounts reclassified from accumulated other comprehensive income (loss)	4,773	3,076
Net current-period other comprehensive (loss) income	5,215	3,076
Balance at the end of the period	(97,107)	(80,071)
Derivatives
Accumulated other comprehensive income activity
Balance at the beginning of the period	(1,362)	(1,677)
Other comprehensive (loss) income before reclassifications	4,066	1,758
Amounts reclassified from accumulated other comprehensive income (loss)	(3,257)	(1,008)
Net current-period other comprehensive (loss) income	809	750
Balance at the end of the period	$ (553)	$ (927)

ACCUMULATED OTHER COMPREHENSI_4

ACCUMULATED OTHER COMPREHENSIVE INCOME - Reclassifications From Accumulated Other Comprehensive Income (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Amount Reclassified from Accumulated Other Comprehensive Income
Interest expense	$ (7,175)	$ (8,734)	$ (14,590)	$ (17,122)
Miscellaneous, net	(2,028)	(923)	(2,991)	(2,335)
Income before Income Taxes	74,294	60,668	175,182	138,704
Tax benefit	(19,020)	(18,808)	(35,969)	(41,594)
Net Income Attributable to AptarGroup, Inc.	55,276	41,839	139,228	97,092
Amount Reclassified from Accumulated Other Comprehensive Income
Amount Reclassified from Accumulated Other Comprehensive Income
Net Income Attributable to AptarGroup, Inc.	3,670	3,975	1,516	2,068
Defined Benefit Pension Plans | Amount Reclassified from Accumulated Other Comprehensive Income
Amount Reclassified from Accumulated Other Comprehensive Income
Amortization of net loss	3,092	1,808	6,184	3,870
Amortization of prior service cost	44	95	89	192
Income before Income Taxes	3,136	1,903	6,273	4,062
Tax benefit	(750)	(463)	(1,500)	(986)
Net Income Attributable to AptarGroup, Inc.	2,386	1,440	4,773	3,076
Derivatives | Amount Reclassified from Accumulated Other Comprehensive Income
Amount Reclassified from Accumulated Other Comprehensive Income
Net Income Attributable to AptarGroup, Inc.	1,284	2,535	(3,257)	(1,008)
Derivatives | Changes in cross currency swap: interest component | Amount Reclassified from Accumulated Other Comprehensive Income
Amount Reclassified from Accumulated Other Comprehensive Income
Interest expense	(6)	(525)	(18)	(1,288)
Derivatives | Changes in cross currency swap: foreign exchange component | Amount Reclassified from Accumulated Other Comprehensive Income
Amount Reclassified from Accumulated Other Comprehensive Income
Miscellaneous, net	$ 1,290	$ 3,060	$ (3,239)	$ 280

DERIVATIVE INSTRUMENTS AND HE_3

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2017
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Net after-tax gain (loss) included in accumulated other comprehensive earnings	$ 289	$ (733)	$ 809	$ 750
Cross Currency Swap Contract | Derivatives in Cash Flow Hedging Relationships
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Amount hedged					$ 280,000
Net after-tax gain (loss) included in accumulated other comprehensive earnings			(600)
Cash flow hedge derivative instrument liability at fair value	4,100		4,100
Interest Rate Swap | Derivatives in Cash Flow Hedging Relationships
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Gain (loss) expected to be recognized in earnings in next twelve months related to cross currency swap contract	$ 800		$ 800
Notes payable
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Proceeds from debt					$ 280,000
Interest rate on notes (as a percent)	1.36%		1.36%		1.36%

DERIVATIVE INSTRUMENTS AND HE_4

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Fair Value of Derivative Instruments in the Consolidated Balance Sheets (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Fair Value of Derivative Instruments
Derivative assets	$ 30	$ 322
Derivative liabilities	5,582	8,455
Foreign Exchange Contracts
Fair Value of Derivative Instruments
Derivative, notional amount	49,900
Derivatives Designated as Hedging Instruments
Fair Value of Derivative Instruments
Derivative assets	0	0
Derivative liabilities	4,056	8,309
Derivatives Designated as Hedging Instruments | Foreign Exchange Contracts | Prepaid and other
Fair Value of Derivative Instruments
Derivative assets	0	0
Derivatives Designated as Hedging Instruments | Foreign Exchange Contracts | Accounts payable, accrued and other liabilities
Fair Value of Derivative Instruments
Derivative liabilities	0	0
Derivatives Designated as Hedging Instruments | Cross Currency Swap Contract | Accounts payable, accrued and other liabilities
Fair Value of Derivative Instruments
Derivative liabilities	4,056	8,309
Derivatives not Designated as Hedging Instruments
Fair Value of Derivative Instruments
Derivative assets	30	322
Derivative liabilities	1,526	146
Derivatives not Designated as Hedging Instruments | Foreign Exchange Contracts | Prepaid and other
Fair Value of Derivative Instruments
Derivative assets	30	322
Derivatives not Designated as Hedging Instruments | Foreign Exchange Contracts | Accounts payable, accrued and other liabilities
Fair Value of Derivative Instruments
Derivative liabilities	1,526	146
Derivatives not Designated as Hedging Instruments | Cross Currency Swap Contract | Accounts payable, accrued and other liabilities
Fair Value of Derivative Instruments
Derivative liabilities	$ 0	$ 0

DERIVATIVE INSTRUMENTS AND HE_5

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Effect of Cash Flow Hedge Accounting on Accumulated Other Comprehensive Income (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Derivative instruments, gain or (loss)
Interest expense	$ (7,175)	$ (8,734)	$ (14,590)	$ (17,122)
Miscellaneous, net	(2,028)	(923)	(2,991)	(2,335)
Derivatives in Cash Flow Hedging Relationships
Derivative instruments, gain or (loss)
Amount of Gain or (Loss) Recognized in OCI on Derivative (Effective Portion)	(995)	(3,268)	4,066	1,758
Amount of Gain (Loss) Reclassified from AOCI on Derivative	(1,284)	(2,535)	3,257	1,008
Changes in cross currency swap: interest component | Derivatives in Cash Flow Hedging Relationships
Derivative instruments, gain or (loss)
Interest expense	(7,175)		(14,590)
Changes in cross currency swap: interest component | Interest expense | Derivatives in Cash Flow Hedging Relationships
Derivative instruments, gain or (loss)
Amount of Gain or (Loss) Recognized in OCI on Derivative (Effective Portion)	295	(208)	827	2,038
Amount of Gain (Loss) Reclassified from AOCI on Derivative	6	525	18	1,288
Changes in cross currency swap: foreign exchange component | Derivatives in Cash Flow Hedging Relationships
Derivative instruments, gain or (loss)
Miscellaneous, net	(2,028)		(2,991)
Changes in cross currency swap: foreign exchange component | Other Income (Expense): Miscellaneous, net | Derivatives in Cash Flow Hedging Relationships
Derivative instruments, gain or (loss)
Amount of Gain or (Loss) Recognized in OCI on Derivative (Effective Portion)	(1,290)	(3,060)	3,239	(280)
Amount of Gain (Loss) Reclassified from AOCI on Derivative	$ (1,290)	$ (3,060)	$ 3,239	$ (280)

DERIVATIVE INSTRUMENTS AND HE_6

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Effect of Derivatives Not Designated as Hedging Instruments on the Condensed Consolidated Statement of Income (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Amount of (Loss) Gain Recognized in Income on Derivatives	$ (1,176)	$ (940)	$ (1,689)	$ 807
Foreign Exchange Contracts
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Amount of (Loss) Gain Recognized in Income on Derivatives	$ (1,176)	$ (940)	$ (1,689)	$ 807

DERIVATIVE INSTRUMENTS AND HE_7

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Schedule of Derivative Assets and Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Derivative Assets
Gross Amount	$ 30	$ 322
Net Amounts Presented in the Statement of Financial Position	30	322
Net Amount	30	322
Derivative Liabilities
Gross Amount	5,582	8,455
Net Amounts Presented in the Statement of Financial Position	5,582	8,455
Net Amount	$ 5,582	$ 8,455

FAIR VALUE - Fair Value of Fina

FAIR VALUE - Fair Value of Financial Assets and Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020	Apr. 01, 2020	Oct. 31, 2019
Liabilities
Fair value of long-term obligations	$ 1,100,000	$ 1,100,000
Fusion Packaging
Liabilities
Fair value of contingent consideration arrangement	28,000		$ 19,100
Percentage of interest acquired			100.00%
Noble
Liabilities
Percentage of interest acquired				100.00%
Level 3
Liabilities
Fair value of contingent consideration arrangement	33,090	31,140
Level 3 | Fusion Packaging
Liabilities
Fair value of contingent consideration arrangement	28,010	26,910
Level 3 | Noble
Liabilities
Fair value of contingent consideration arrangement	5,080	4,230
Assets and liabilities measured at fair value on recurring basis
Assets
Investment in equity securities	20,595
Foreign exchange contracts, assets	30	322
Total assets at fair value	20,625	322
Liabilities
Foreign exchange contracts, liabilities	1,526	146
Cash flow hedge derivative instrument liability at fair value	4,056	8,309
Fair value of contingent consideration arrangement	33,090	31,140
Total liabilities at fair value	38,672	39,595
Assets and liabilities measured at fair value on recurring basis | Level 1
Assets
Investment in equity securities	20,595
Foreign exchange contracts, assets	0	0
Total assets at fair value	20,595	0
Liabilities
Foreign exchange contracts, liabilities	0	0
Cash flow hedge derivative instrument liability at fair value	0	0
Fair value of contingent consideration arrangement	0	0
Total liabilities at fair value	0	0
Assets and liabilities measured at fair value on recurring basis | Level 2
Assets
Investment in equity securities	0
Foreign exchange contracts, assets	30	322
Total assets at fair value	30	322
Liabilities
Foreign exchange contracts, liabilities	1,526	146
Cash flow hedge derivative instrument liability at fair value	4,056	8,309
Fair value of contingent consideration arrangement	0	0
Total liabilities at fair value	5,582	8,455
Assets and liabilities measured at fair value on recurring basis | Level 3
Assets
Investment in equity securities	0
Foreign exchange contracts, assets	0	0
Total assets at fair value	0	0
Liabilities
Foreign exchange contracts, liabilities	0	0
Cash flow hedge derivative instrument liability at fair value	0	0
Fair value of contingent consideration arrangement	33,090	31,140
Total liabilities at fair value	$ 33,090	$ 31,140

FAIR VALUE - Contingent Conside

FAIR VALUE - Contingent Consideration Fair Value (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020	Apr. 01, 2020
Level 3
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair value of contingent consideration arrangement	$ 33,090	$ 31,140
Fusion Packaging
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair value of contingent consideration arrangement	28,000		$ 19,100
Fusion Packaging | Level 3
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair value of contingent consideration arrangement	28,010	26,910
Noble | Level 3
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair value of contingent consideration arrangement	$ 5,080	$ 4,230

FAIR VALUE - Roll Forward (Deta

FAIR VALUE - Roll Forward (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2021USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance at beginning of period	$ 31,140
Increase in fair value recorded in earnings	1,950
Balance at end of period	$ 33,090

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details) - USD ($)	Jun. 30, 2021	Dec. 31, 2020	Jun. 30, 2020	Dec. 31, 2019
Brazil | Reduction of gross receipts tax
Commitments and contingencies
Recovery of part of claim	$ 1,600,000		$ 700,000
Brazil | Reduction of gross receipts tax | Minimum
Commitments and contingencies
Estimated potential gain contingency, recoveries	3,000,000
Brazil | Reduction of gross receipts tax | Maximum
Commitments and contingencies
Estimated potential gain contingency, recoveries	6,000,000
Indemnification agreements
Commitments and contingencies
Liabilities recorded under indemnification agreements	0	$ 0
Tax Assessment | Brazil
Commitments and contingencies
Estimated loss contingency				$ 6,100,000
Loss contingency liability recorded	$ 0
Tax Assessment, Interest | Brazil
Commitments and contingencies
Estimated loss contingency				2,300,000
Tax Assessment, Penalites | Brazil
Commitments and contingencies
Estimated loss contingency				$ 800,000

STOCK REPURCHASE PROGRAM (Detai

STOCK REPURCHASE PROGRAM (Details) - USD ($)	Jun. 30, 2021	Apr. 18, 2019
Stock repurchase program
Remaining authorized repurchase amount	$ 278,500,000
Stock Repurchase Program April 18, 2019
Stock repurchase program
Share repurchases authorized amount		$ 350,000,000

STOCK-BASED COMPENSATION - Narr

STOCK-BASED COMPENSATION - Narrative (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award
Proceeds from stock option exercises	$ 53,038	$ 30,058
Time-Based RSUs
Share-based Compensation Arrangement by Share-based Payment Award
Vesting period (in years)	3 years
RSU's granted (in shares)	140,316
RSU's vested (in shares)	134,808
Time-Based RSUs | Director Stock Option Plans
Share-based Compensation Arrangement by Share-based Payment Award
RSU's granted (in shares)	10,007
RSU's vested (in shares)	12,379
Performance-Based RSUs
Share-based Compensation Arrangement by Share-based Payment Award
Vesting period (in years)	3 years
RSU's granted (in shares)	169,974
RSU's vested (in shares)	71,994
Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award
Tax benefit	$ 4,000
Unrecognized compensation expense	$ 61,300
Weighted-average period cost will be recognized over	2 years
Restricted Stock Units | Director Stock Option Plans
Share-based Compensation Arrangement by Share-based Payment Award
Vesting period (in years)	1 year
Options
Share-based Compensation Arrangement by Share-based Payment Award
Vesting period (in years)	3 years
Tax benefit	$ 15,000	$ 6,400
Expiration period	10 years
Proceeds from stock option exercises	$ 53,000

STOCK-BASED COMPENSATION - Assu

STOCK-BASED COMPENSATION - Assumptions Used (Details) - Performance-Based RSUs - $ / shares	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award
Fair value per stock award (in dollars per share)	$ 171.63	$ 94.98
Grant date stock price (in dollars per share)	$ 141.59	$ 83.93
Aptar's stock price expected volatility	21.40%	23.80%
Expected average volatility of peer companies	50.00%	48.50%
Correlation assumption	58.10%	63.50%
Risk-free interest rate	0.32%	0.31%
Dividend yield assumption	1.02%	1.72%

STOCK-BASED COMPENSATION - Rest

STOCK-BASED COMPENSATION - Restricted Stock Unit Activity (Details)	6 Months Ended
	Jun. 30, 2021$ / sharesshares
Time-Based RSUs
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]
Nonvested outstanding beginning balance (in shares) | shares	576,198
RSU's granted (in shares) | shares	140,316
Vested (in shares) | shares	(134,808)
Restricted stock units forfeited (in shares) | shares	(3,244)
Nonvested outstanding ending balance (in shares) | shares	578,462
Weighted Average Grant Date Fair Value
Outstanding, Weighted average grant date fair value begging balance (in dollars per share) | $ / shares	$ 92.47
Granted, Weighted average grant date fair value (in dollars per share) | $ / shares	139.25
Vested, Weighted average grant date fair value (in dollars per share) | $ / shares	91.39
Forfeited, Weighted average grant date fair value (in dollars per share) | $ / shares	99.42
Outstanding, Weighted average grant date fair value ending balance (in dollars per share) | $ / shares	$ 107.45
Performance-Based RSUs
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]
Nonvested outstanding beginning balance (in shares) | shares	590,064
RSU's granted (in shares) | shares	169,974
Vested (in shares) | shares	(71,994)
Restricted stock units forfeited (in shares) | shares	(31,872)
Nonvested outstanding ending balance (in shares) | shares	656,172
Weighted Average Grant Date Fair Value
Outstanding, Weighted average grant date fair value begging balance (in dollars per share) | $ / shares	$ 100.27
Granted, Weighted average grant date fair value (in dollars per share) | $ / shares	152.51
Vested, Weighted average grant date fair value (in dollars per share) | $ / shares	128.70
Forfeited, Weighted average grant date fair value (in dollars per share) | $ / shares	91.67
Outstanding, Weighted average grant date fair value ending balance (in dollars per share) | $ / shares	$ 111.10

STOCK-BASED COMPENSATION - Comp

STOCK-BASED COMPENSATION - Compensation Expense (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award
Compensation expense	$ 21,579	$ 16,353
Fair value of units vested	20,778	10,696
Intrinsic value of units vested	28,259	12,821
Options
Share-based Compensation Arrangement by Share-based Payment Award
Compensation expense	227	1,251
Compensation expense, net of tax	174	951
Grant date fair value of options vested	2,421	7,565
Options | Selling Research And Development And Administrative Expenses
Share-based Compensation Arrangement by Share-based Payment Award
Compensation expense	185	1,051
Options | Cost of Sales
Share-based Compensation Arrangement by Share-based Payment Award
Compensation expense	$ 42	$ 200

STOCK-BASED COMPENSATION - Summ

STOCK-BASED COMPENSATION - Summary of Option Activity (Details) - Options - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Stock Awards Plans
Stock options activity
Outstanding at the beginning of the period (in shares)	3,998,047
Granted (in shares)	0
Exercised (in shares)	(816,058)
Forfeited or expired (in shares)	(10,153)
Outstanding at the end of the period (in shares)	3,171,836
Stock option weighted average exercise price
Outstanding at the beginning of the period (in dollars per share)	$ 70.28
Options granted, Weighted average exercise price per share (in dollars per share)	0
Options exercised, Weighted average exercise price per share (in dollars per share)	64.74
Options forfeited or expired, Weighted average exercise price per share (in dollars per share)	75.46
Outstanding at the end of the period (in dollars per share)	$ 71.69
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Options exercisable, Number of options (in shares)	3,171,836
Options exercisable, Weighted average exercise price per share (in dollars per share)	$ 71.69
Options outstanding, Weighted average remaining contractual term (in years)	4 years 6 months
Options exercisable, Weighted average remaining contractual term (in years)	4 years 6 months
Options outstanding, Aggregate intrinsic value (in USD)	$ 221,908
Options exercisable, Aggregate intrinsic value (in USD)	221,908
Options exercised, Intrinsic value, at end of period	$ 63,407	$ 26,027
Director Stock Option Plans
Stock options activity
Outstanding at the beginning of the period (in shares)	99,200
Granted (in shares)	0
Exercised (in shares)	(47,500)
Forfeited or expired (in shares)	0
Outstanding at the end of the period (in shares)	51,700
Stock option weighted average exercise price
Outstanding at the beginning of the period (in dollars per share)	$ 60.80
Options granted, Weighted average exercise price per share (in dollars per share)	0
Options exercised, Weighted average exercise price per share (in dollars per share)	57.40
Options forfeited or expired, Weighted average exercise price per share (in dollars per share)	0
Outstanding at the end of the period (in dollars per share)	$ 63.91
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Options exercisable, Number of options (in shares)	51,700
Options exercisable, Weighted average exercise price per share (in dollars per share)	$ 63.91
Options outstanding, Weighted average remaining contractual term (in years)	2 years 7 months 6 days
Options exercisable, Weighted average remaining contractual term (in years)	2 years 7 months 6 days
Options outstanding, Aggregate intrinsic value (in USD)	$ 4,019
Options exercisable, Aggregate intrinsic value (in USD)	4,019
Options exercised, Intrinsic value, at end of period	$ 4,248	$ 1,973

EARNINGS PER SHARE (Details)

EARNINGS PER SHARE (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Numerator
Income available to common stockholders, Diluted	$ 55,276	$ 41,839	$ 139,228	$ 97,092
Income available to common stockholders, Basic	$ 55,276	$ 41,839	$ 139,228	$ 97,092
Denominator (Shares)
Basic (in shares)	65,818	64,262	65,525	64,135
Effect of dilutive stock-based compensation
Diluted (in shares)	68,086	66,384	67,869	66,246
Per Share Amount
Diluted (in dollars per share)	$ 0.81	$ 0.63	$ 2.05	$ 1.47
Basic (in dollars per share)	$ 0.84	$ 0.65	$ 2.12	$ 1.51
Options
Effect of dilutive stock-based compensation
Incremental common shares attributable to dilutive effect of share-based payment arrangements (in shares)	1,727	1,661	1,804	1,734
Restricted Stock Units
Effect of dilutive stock-based compensation
Incremental common shares attributable to dilutive effect of share-based payment arrangements (in shares)	541	461	540	377

SEGMENT INFORMATION - Summary o

SEGMENT INFORMATION - Summary of Reportable Segments (Details) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021USD ($)	Jun. 30, 2020USD ($)	Jun. 30, 2021USD ($)segment	Jun. 30, 2020USD ($)
Segment Reporting [Abstract]
Number of reportable segments | segment			3
Financial information regarding the Company's reportable segments
Net Sales	$ 811,032	$ 699,305	$ 1,587,786	$ 1,420,858
Acquisition related costs	(2,434)	(3,592)	(2,434)	(5,866)
Restructuring initiatives	(4,876)	(7,331)	(8,548)	(12,170)
Net investment (loss) gain	(1,611)	0	15,198	0
Depreciation and amortization	(57,790)	(56,429)	(115,228)	(107,235)
Interest expense	(7,175)	(8,734)	(14,590)	(17,122)
Interest income	624	175	1,005	350
Income before Income Taxes	74,294	60,668	175,182	138,704
Pharma
Financial information regarding the Company's reportable segments
Net Sales	325,343	301,259	639,175	598,455
Adjusted EBITDA	105,979	104,099	214,463	212,441
Restructuring initiatives	(38)	111	(73)	142
Beauty + Home
Financial information regarding the Company's reportable segments
Net Sales	360,246	299,786	707,192	624,346
Adjusted EBITDA	37,910	23,974	73,266	58,221
Restructuring initiatives	(1,457)	(7,324)	(2,553)	(12,231)
Food + Beverage
Financial information regarding the Company's reportable segments
Net Sales	125,443	98,260	241,419	198,057
Adjusted EBITDA	19,626	17,785	39,616	33,192
Restructuring initiatives	(117)	(75)	(38)	(178)
Corporate & Other, unallocated
Financial information regarding the Company's reportable segments
Adjusted EBITDA	(15,959)	(9,279)	(27,566)	(23,107)
Restructuring initiatives	(3,264)	(43)	(5,884)	97
Operating segment
Financial information regarding the Company's reportable segments
Net Sales	821,108	709,377	1,606,999	1,439,734
Operating segment | Pharma
Financial information regarding the Company's reportable segments
Net Sales	328,549	303,885	644,360	603,475
Operating segment | Beauty + Home
Financial information regarding the Company's reportable segments
Net Sales	366,641	306,469	720,018	636,935
Operating segment | Food + Beverage
Financial information regarding the Company's reportable segments
Net Sales	125,918	99,023	242,621	199,324
Intersegment
Financial information regarding the Company's reportable segments
Net Sales	10,076	10,072	19,213	18,876
Intersegment | Pharma
Financial information regarding the Company's reportable segments
Net Sales	3,206	2,626	5,185	5,020
Intersegment | Beauty + Home
Financial information regarding the Company's reportable segments
Net Sales	6,395	6,683	12,826	12,589
Intersegment | Food + Beverage
Financial information regarding the Company's reportable segments
Net Sales	$ 475	$ 763	$ 1,202	$ 1,267

ACQUISITIONS - Narrative (Detai

ACQUISITIONS - Narrative (Details) € / shares in Units, $ in Thousands, € in Millions	Dec. 31, 2021USD ($)	Dec. 31, 2021EUR (€)€ / shares€ / $	Oct. 16, 2020USD ($)	Apr. 01, 2020USD ($)	Sep. 30, 2021USD ($)	Dec. 31, 2020USD ($)	Sep. 30, 2020USD ($)	Jun. 30, 2021USD ($)	Jun. 30, 2020USD ($)
Acquisitions
Payments to acquire businesses, net of cash acquired								$ 4,834	$ 159,570
Restricted cash included in prepaid and other								0	$ 9,738
Goodwill						$ 898,521		887,741
Cohero Health, Inc.
Acquisitions
Asset acquisition, consideration transferred			$ 2,400
Voluntis | Forecast
Acquisitions
Percentage of interest acquired		100.00%
Percentage of interest acquired of management and certain shareholders		0.646
Business acquisition, share price (in Euros per share) | € / shares		€ 8.70
Foreign exchange rate (Euro/USD) | € / $		1.21
Valuation of full company equity of acquired company	$ 95,300	€ 78.8
Payments to Acquire Businesses, Gross	$ 61,500	€ 50.8
Pharma Manufacturing Company | Forecast
Acquisitions
Percentage of interest acquired					80.00%
Enterprise valuation of company acquired					$ 77,000
Remaining percentage of interest to be acquired					0.20
Lock up period (in years)					5 years
Fusion Packaging
Acquisitions
Percentage of interest acquired				100.00%
Payments to acquire businesses, net of cash acquired				$ 163,800
Cash and equivalents				1,000
Fair value of contingent consideration arrangement				19,100				$ 28,000
Fair value true-up for contingent consideration liability						3,600
Restricted cash included in prepaid and other				$ 5,700
Release of working capital escrow							$ 2,000
Proceeds from release of working capital escrow refunded to buyer							$ 294
Goodwill						103,100
2020 Acquisitions
Acquisitions
Cash and equivalents						1,010
Goodwill						103,130
Goodwill deductible for tax purposes						$ 80,600

ACQUISITIONS - Assets Acquired

ACQUISITIONS - Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Assets
Goodwill	$ 887,741	$ 898,521
2020 Acquisitions
Assets
Cash and equivalents		1,010
Accounts receivable		4,380
Inventories		386
Prepaid and other		1,090
Property, plant and equipment		2,885
Goodwill		103,130
Intangible assets		79,900
Operating lease right-of-use assets		4,744
Other miscellaneous assets		65
Liabilities
Accounts payable, accrued and other liabilities		5,641
Deferred income taxes		0
Operating lease liabilities		4,207
Deferred and other non-current liabilities		322
Net assets acquired		$ 187,420

ACQUISITIONS - Acquired Intangi

ACQUISITIONS - Acquired Intangibles (Details) - 2020 Acquisitions $ in Thousands	12 Months Ended
	Dec. 31, 2020USD ($)
Acquired finite-lived intangible assets
Estimated Fair Value of Asset	$ 79,900
Acquired technology
Acquired finite-lived intangible assets
Weighted average useful life (in years)	4 years
Estimated Fair Value of Asset	$ 4,600
Customer relationships
Acquired finite-lived intangible assets
Weighted average useful life (in years)	13 years
Estimated Fair Value of Asset	$ 62,300
Trademarks and trade names
Acquired finite-lived intangible assets
Weighted average useful life (in years)	4 years
Estimated Fair Value of Asset	$ 10,300
License agreements and other
Acquired finite-lived intangible assets
Weighted average useful life (in years)	3 months
Estimated Fair Value of Asset	$ 2,700

INVESTMENT IN EQUITY SECURITI_3

INVESTMENT IN EQUITY SECURITIES - Schedule of Investments (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Schedule of Equity Method Investments [Line Items]
Total equity method investments and other investments	$ 65,200	$ 50,087
BTY
Schedule of Equity Method Investments [Line Items]
Equity method investments	33,005	33,020
Sonmol
Schedule of Equity Method Investments [Line Items]
Equity method investments	5,710	5,598
Kali Care
Schedule of Equity Method Investments [Line Items]
Equity method investments	422	535
Desotec GmbH
Schedule of Equity Method Investments [Line Items]
Equity method investments	943	964
Purecycle
Schedule of Equity Method Investments [Line Items]
Other investments	20,595	5,397
Loop
Schedule of Equity Method Investments [Line Items]
Other investments	2,894	2,894
Others
Schedule of Equity Method Investments [Line Items]
Other investments	$ 1,631	$ 1,679

INVESTMENT IN EQUITY SECURITI_4

INVESTMENT IN EQUITY SECURITIES - Narrative (Details) € in Thousands

Jul. 07, 2021USD ($)

Apr. 01, 2020USD ($)

Jan. 01, 2020USD ($)

Nov. 30, 2020USD ($)

Aug. 31, 2019USD ($)investment

Jun. 30, 2021USD ($)

Dec. 31, 2020USD ($)

Jun. 30, 2021USD ($)

Jun. 30, 2020USD ($)

Dec. 31, 2020USD ($)

Dec. 31, 2017USD ($)

Dec. 31, 2009EUR (€)

Mar. 31, 2021

Schedule of Equity Method Investments [Line Items]

Investment in unconsolidated affiliate

$ 0

$ 34,044,000

Investment impairment

0

BTY

Schedule of Equity Method Investments [Line Items]

Ownership percentage of equity method investment

49.00%

Equity method investments

$ 33,005,000

$ 33,020,000

33,005,000

$ 33,020,000

Initial lock-up period (in years)

5 years

Second lock-up period (in years)

3 years

Investment in unconsolidated affiliate

$ 32,000,000

BTY | Call Option | Minimum

Schedule of Equity Method Investments [Line Items]

Ownership percentage of equity method investment

26.00%

BTY | Call Option | Maximum

Schedule of Equity Method Investments [Line Items]

Ownership percentage of equity method investment

31.00%

Sonmol

Schedule of Equity Method Investments [Line Items]

Ownership percentage of equity method investment

30.00%

Equity method investments

5,710,000

5,598,000

5,710,000

5,598,000

Investment in unconsolidated affiliate

$ 5,000,000

Kali Care

Schedule of Equity Method Investments [Line Items]

Ownership percentage of equity method investment

20.00%

Equity method investments

422,000

535,000

422,000

535,000

Investment in unconsolidated affiliate

$ 5,000,000

Investment impairment

3,000,000

Investment impairment, net

2,300,000

Desotec GmbH

Schedule of Equity Method Investments [Line Items]

Ownership percentage of equity method investment

23.00%

Equity method investments

943,000

$ 964,000

943,000

964,000

Investment in unconsolidated affiliate | €

€ 574

Loop and Purecycle | Preferred stock

Schedule of Equity Method Investments [Line Items]

Investment in unconsolidated affiliate

$ 3,500,000

Number of preferred equity investments | investment

2

Increase (decrease) in value of preferred equity stock investment

1,400,000

YAT | Subsequent Event

Schedule of Equity Method Investments [Line Items]

Investment in unconsolidated affiliate

$ 5,900,000

Investment ownership percentage

0.10

Purecycle

Schedule of Equity Method Investments [Line Items]

Investment ownership percentage

0.01

Unrealized gain (loss) on investments

$ (1,600,000)

$ 15,200,000

Purecycle | Preferred stock

Schedule of Equity Method Investments [Line Items]

Equity received in exchange for services

$ 333,000

Increase (decrease) in value of preferred equity stock investment

$ 3,100,000

RESTRUCTURING INITIATIVES - Nar

RESTRUCTURING INITIATIVES - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Restructuring Cost and Reserve [Line Items]
Restructuring initiatives	$ 4,876	$ 7,331	$ 8,548	$ 12,170
Capital expenditures			137,039	122,986
Business Transformation
Restructuring Cost and Reserve [Line Items]
Restructuring initiatives	4,900	$ 7,300	8,500	$ 12,200
Expected implementation costs	125,000		125,000
Cumulative expense incurred	$ 121,500		121,500
Capital expenditures			$ 50,000

RESTRUCTURING INITIATIVES - Bus

RESTRUCTURING INITIATIVES - Business Transformation Activity (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Restructuring reserve
Restructuring reserve, balance at the beginning of the period			$ 10,489
Net Charges	$ 4,876	$ 7,331	8,548	$ 12,170
Cash Paid			(13,047)
Interest and FX Impact			(156)
Restructuring reserve, balance at the end of the period	5,834		5,834
Employee severance
Restructuring reserve
Restructuring reserve, balance at the beginning of the period			7,956
Net Charges			144
Cash Paid			(3,616)
Interest and FX Impact			(130)
Restructuring reserve, balance at the end of the period	4,354		4,354
Professional fees and other costs
Restructuring reserve
Restructuring reserve, balance at the beginning of the period			2,533
Net Charges			8,404
Cash Paid			(9,431)
Interest and FX Impact			(26)
Restructuring reserve, balance at the end of the period	$ 1,480		$ 1,480

SUBSEQUENT EVENTS (Details)

SUBSEQUENT EVENTS (Details) $ in Thousands	Jul. 07, 2021USD ($)	Jun. 30, 2021USD ($)	Jun. 30, 2020USD ($)	Dec. 31, 2021€ / shares
Subsequent Event [Line Items]
Investment in unconsolidated affiliate		$ 0	$ 34,044
YAT | Subsequent Event
Subsequent Event [Line Items]
Investment in unconsolidated affiliate	$ 5,900
Investment ownership percentage	0.10
Forecast | Voluntis
Subsequent Event [Line Items]
Percentage of interest acquired of management and certain shareholders				0.646
Business acquisition, share price (in Euros per share) | € / shares				€ 8.70

Uncategorized Items - atr-20210

Label	Element	Value
Accounting Standards Update [Extensible List]	us-gaap_AccountingStandardsUpdateExtensibleList	Accounting Standards Update 2016-13 [Member]